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Abacavir ProTides  
Zhiyi Lin, Ph.D. 
University of Nebraska Medical Center, 2019 
Supervisor: Howard E Gendelman, M.D. 
Combination antiretroviral therapy (cART) for treatment of human immunodeficiency 
virus (HIV) infection demands life-long regimen adherence. Treatment interruptions lead 
to a lack of virologic control and the emergence of viral mutations and drug resistance. To 
address these, our laboratory developed long-acting (LA) parenteral administered 
nanoformulated abacavir prodrug (NMABC) by formulating myristoylated abacavir (MABC) 
with poloxamer 407 as stabilizer, which sustained ABC levels for up to 2 weeks with low 
levels of active drug metabolite (CBV-TP). To more significantly extend the apparent half-
life of ABC and improve its antiretroviral activities, we developed second generation long-
acting ABC prodrugs by ProTide technologies. This modification can deliver pre-activated 
nucleoside analog inside the target cells. The work proceeded in defined manner.  
First, we synthesized then characterized traditional ProTides of ABC, AlaMe, with 
ProTide technology. The antiretroviral activity (EC50) of AlaMe was 7-fold lower then native 
ABC. Then, AlaMe loaded and lipid coated PLGA nanoparticle was prepared withna size 
of 250 nm by thin film hydration (NAlaMe). NAlaMe can be easily taken up and retained 
by monocyte-derived macrophages (MDM) for weeks and protect MDM against HIV 
infections. Male BALB/cJ mice were subcutaneously administered 54.3mg/kg ABC 
equivalents of NAlaMe and ABC. NAlaMe treated mice had higher CBV-TP levels than 
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ABC at 24 and 72 h after administration. These results showed that ProTide technologies 
can be a useful strategy for the development of second-generation ABC LA.   
Second, ProTide technology was combined with LA technology. Three ABC ProTides 
(AlaMe, PheMe and PheC22) were successfully synthesized. AlaMe and PheMe were 
traditional ProTides. PheC22 possessed a long-chain fatty alcohol moiety. All three 
ProTides demonstrated improved antiretroviral activities compared to ABC. 
Nanosuspensions of PheMe (NPheMe) and PheC22 (NPheC22) were formulated using 
P407 as stabilizer with sizes of 388 and 340 nm, respectively. Cell uptake, retention and 
antiretroviral activity of NAlaMe, NPheMe, NPheC22 were tested in MDM. NPheC22 had 
the highest uptake, retention and was able to protect MDM against HIV-1 infection up to 
30 days. Combinatorial strategies thus show advantages for the development of second-
generation ABC LA. ABC ProTides had long-chain fatty esters were specifically named 
ABC ProTides LA. 
Third, we investigated the influence of different combination of amino acid and long-
chain fatty alcohol on activities of ABC ProTides LA. Six ABC ProTides LA: AlaC14, 
AlaC18, AlaC22, PheC14, PheC18 and PheC22 were synthesized and characterized. The 
EC50 of ABC ProTides were up to 100- or 10-fold lower in MDM or CEM CD4+T cells 
against HIV infection compared to ABC. CBV-TP was increased by up to 45-fold of 8-fold 
in MDM or CEM CD4+T cells. Nanosuspension of all six ProTides were formulated using 
DSPG-mPEG2K and Tween 80 as stabilizers. The six nanosuspension had sizes range 
from 220 - 300 nm. Nanosuspensions were taken up, retained and released by MDM and 
protected MDM against HIV-1 infection more than 28 days. PK studies in rats showed that 
ProTide nanosuspension provide CBV-TP over a longer time than ABC. NAlaC18 
provided clinically relevant CBV-TP levels in rats up to 7 days following a single injection. 
In conclusion, ProTides and LA technologies were combinationally used to create second 
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generation ABC LA. These works are a step forward in the development of long acting 
nucleoside reverse transcriptase inhibitors for human use. 
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1.1 HIV/AIDS epidemic 
In June 5th, 1981, the U.S. Center for Disease Control (CDC) published an article 
named “Pneumocystis Pneumonia – Los Angeles” in its Morbidity and Mortality Weekly 
Report (MMWR). This article described 5 cases of a rare lung infection, Pneumocystis 
carinii pneumonia (PCP) in young, white, previously healthy gay men. These men had 
other unusual infections which indicated that their immune systems were dysfunctional. 
That was the first official report of what later would become the Acquired 
immunodeficiency Syndrome or AIDS and the disease epidemic as we know it today.  
Two year later, Drs. Françoise Barré-Sinoussi and Luc Montagnier and their 
colleagues at the Pasteur Institute in France reported the discovery of a retrovirus that 
could be the cause of the new disease but it was Dr. Robert Gallo that firmly established 
that the new virus now named the human immunodeficiency virus (HIV) was the cause of 
AIDS. Drs. Françoise Barré-Sinoussi and Luc Montagnier won Nobel Prize in Medicine 
and Physiology in 2008. 
In May 1st, 1986, the International Committee on the Taxonomy of Viruses announced 
the retrovirus that causes AIDS will be officially named as “Human Immuodeficiency Virus” 
(HIV). In March 19th, 1987, almost six year after the first report on AIDS, the U.S. Food 
and Drug Administration (FDA) approved the first medication zidovudine (AZT) for AIDS. 
This drug was originally designed to treat cancer. In 1992, AIDS was the number one 
cause of death for U.S. men ages 25 to 44. Then, it became the leading cause of death 
for all Americans ages 25 to 44 in 1994. By October 31st, 1995, 500,000 cases of AIDS 
have been reported in the U.S. Also, in 1995, FDA approved the first protease inhibitor 
which brought in the era of combination antiretroviral therapy (cART), also called highly 
active antiretroviral therapy (HAART), which changed the course of the disease to one of 
certain death to a manageable chronic disorder. 
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In 1996, Vancouver, Canada, the 11th international AIDS Conference highlighted the 
effectiveness of HAART. The number of newly diagnosed AIDS cased in the U.S. was 
declined for the first time since the beginning of the HIV/AIDS epidemic. In 1997, HAART 
became the new standard of HIV/AIDS treatment. And the CDC reported first substantial 
decline, a 47% decline as compared to the previous year, in AIDS death in the U.S. 
According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), 39 million 
people out of the 76.1 million who had been infected have died of HIV/AIDS since the 
beginning of epidemic. And there were still approximately 36.9 million people worldwide 
living with HIV/AIDS in 2017. 
1.2 HIV life cycle 
As shown in Figure 1.1, there are seven stages of the HIV life cycle: 1) binding, 2) 
fusion, 3) reverse transcription, 4) integration, 5) replication, 6) assembly and 7) budding.  
In the first stage, virions bind to the target cell mediated by the viral envelope (Env) 
with its primary receptor, the host protein CD41. Then, Env will change its conformation 
and binds to coreceptors. There are two coreceptors and HIV strains can be broadly 
classified based on their coreceptor usages. Viruses use chemokine coreceptor CCR5 are 
termed R5, others use CXCR4 are termed X4, and viruses that use both coreceptors are 
called R5X4. Coreceptor binding is widely thought to be the trigger that activates the 
membrane fusion potential of Env, and the viral contents will be subsequently delivered 
into the host cell cytoplasm. In the third stage, the viral single-stranded RNAs are 
transcribed into double-stranded DNAs by reverse transcription (RT). Reverse 
transcription is initiated shortly after virus entry: Viral DNA can be detected within hours of 
infection. The rate of HIV-1 DNA synthesis had been measured in 293T cells and activated 
primary human CD4+ T cells: minus-strand DNA is synthesized at a rate of ~70 nucleotides 
per minute. Plus-strand DNA synthesis is rapid possibly because multiple initiation sites 
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are used2. Then, viral DNAs will be integrated into the host cell chromosome by virus-
encoded integrase protein. Once integrated, the proviral DNA will be replicated along with 
cellular DNA during cell division cycles. The provirus serves as the template for 
transcription of viral RNAs. Some viral RNAs are translated to yield the viral proteins, 
whereas a portion of the full-length viral RNA is recruited to serve as genomic RNA in 
progeny virions3. 
HIV-1 virion assembly occurs at the plasma membrane, and all essential events are 
mediated by HIV-1 Gag polyprotein including binding to the plasma membrane, making 
the protein-protein interaction to create spherical particles, concentrating the viral Env 
protein, and packaging the genomic RNA via direct interactions with the RNA packaging 
sequence. The budding event that releases the virion from the plasma membrane is 
mediated by the host endosomal sorting complexes required for transport (ESCRT) 
machinery4. 
1.3 Antiretroviral Drug (ARV) 
Antiretroviral drug (ARV) is medicine for the treatment of infection by retroviruses, 
primarily HIV. FDA have approved more than 30 ARV in seven mechanistic classes that 
act on different stages of HIV life cycle. Nucleoside reverse transcriptase inhibitors 
(NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) inhibit the reverse 
transcription of HIV. Protease inhibitors (PIs) block HIV protease that is essential for the 
maturation of virions. Integrase inhibitors (INIs), also known as integrase strand transfer 
inhibitors (INSTIs), stop HIV integration that mediate the integration of viral DNA to host 
cell DNA. All other drugs include a fusion inhibitor, a CCR5 antagonist, and a CD4 post-
attachment inhibitor. In addition, two drugs, ritonavir (RTV or r) and cobicistat (COBI or c) 
are used as pharmacokinetic (PK) enhancers. 
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1.4 Combination Antiretroviral Therapy (cART) 
Combination antiretroviral therapy (cART) is now recommended for everyone infected 
with HIV starting immediately after diagnosis. Initial cART for a treatment-naïve patient 
generally includes two NRTIs, usually abacavir/lamivudine (ABC/3TC), or tenofovir 
alafenamide/emtricitabine (TAF/FTC), tenofovir disoproxil fumarate (TDF)/FTC, plus a 
drug from one of three drug classes, an INSTI, an NNRTI, or a boosted PI. Coformulated 
fixed-dose tablets consist of various combinations of ARV are developed to facilitate 
adherence include Epzicom (ABC/3TC), Triumeq (DTG/ABC/3TC), Biktarvy (bictegravir, 
BIC/FTC/TAF), etc.  
1.5 Abacavir (ABC) 
ABC is an NRTI approved by FDA under the brand name of Ziagen in 1998 and used 
as either a 600-mg once-daily or 300-mg twice-daily regimen. ABC is rapidly absorbed 
after oral administration with absolute bioavailability of ABC is approximately 83%. Food 
do not significantly affect ABC exposure; therefore, ABC can be administered with or 
without food5.  
The in vivo metabolism of ABC is summary in Figure 1.2. ABC is extensively 
metabolized by the liver with only 2% is excreted as unchanged drug in the urine. There 
are two primary metabolism pathways for ABC. Metabolism by alcohol dehydrogenase 
(ADH) results in the inactive carboxylate metabolite ABC-carboxylate (2269W93). 
Metabolism by uridine diphosphate glucanosyltransferase (UGT) enzymes results in the 
inactive glucuronide metabolite ABC-glucuronide (361W94). In a mass balance study 
using [(14)C] abacavir, ABC and its two major metabolites accounted for the majority (92%) 
radioactivity detected in plasma. 83% of the original dose was eliminated in the urine, and 
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16% eliminated in feces. 36% radioactivity dose was identified as 361W94 and 30% was 
identified as 2269W93 out of the 83% radioactivity dos eliminated in the urine6. 
Concurrently, once inside the cell, ABC is phosphorylated to ABC monophosphate 
(ABC-MP) by adenosine phosphotransferase, followed by deamination by a unique 
cytosolic enzyme to cabover monophosphate (CBV-MP). Then, CBV-MP is converted to 
CBV diphosphate (CBV-DP) and finally to CBV triphosphate (CBV-TP) by other kinases. 
CBV-TP is the active metabolite, which competes with endogenous nucleotide 2’-
deoxyguanosine triphosphate for incorporation into the nucleic acid chain. And since it 
lacks of the 3’-OH on the deoxyribose sugar, after incorporation, it will terminate the 
synthesis of viral DNA chain by preventing addition of new base catabolized by HIV-RT7. 
The terminal elimination half-life (t1/2b) of ABC is reported to be 2.59 hours which is not 
clinically important because it is antiretroviral effect is due to CBV-TP, which has a long 
t1/2b (20.64 hours)8. 
CBV-TP is selective for the HIV-RT when compared with DNA polymerase a, b, g, and 
e. The inhibition constant (Ki) of ABC for HIV-RT is 21 nmol/L. This Ki is 90-, 2900-, 1200, 
and 1900-fold greater for DNA polymerase a, b, g, and e, respectively.  
Clinical trials have shown that ABC, as part of an NRTI backbone, is generally well 
tolerated. The most common drug-related adverse events are nausea, vomiting, fatigue, 
headache, and diarrhea. The frequency of adverse events drops dramatically with 
continued treatment.  
Five percent of adult patients experience a hypersensitivity reaction (HSR) to ABC. 
The symptoms include fever, rash, gastrointestinal symptoms (nauseam vomiting, 
diarrhea or abdominal pain), generalized malaise or lethargy with or without concomitant 
respiratory symptoms or other less frequent symptoms such as musculoskeletal 
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symptoms and headache. HSR can be resolved without sequalae once abacavir was 
discontinued and the patient should not be rechallenged. Studies suggested HSR is 
strongly related to HLA-B*5701 allele carriage9-11. Treatment guidelines for HIV were 
revised in 2008 to require (depending on region) or recommend HLA-B*5701 screening 
for all patients before ABC treatment is initiated. 
1.6 nanoformulated ART (nanoART) 
1.6.1 Nanotechnology 
Nanotechnology is the engineering and manufacturing of materials at the atomic and 
molecular scale. Nanomedicine, according to National Institutes of Health (NIH), is the 
application of nanotechnology to disease treatment, diagnosis, monitoring, and for 
biological control. Rational design of nanoformulations for the delivery of therapeutic 
agents including small molecule drugs, peptides or proteins, and genes are the most 
active research areas for nanomedicine. Many reviews have been published to showcase 
the management of HIV infection through application of nanoformulations12. The 
nanoparticle sizes of researched nanoformulations range from 1 to 1000 nm, which give 
them unique physical, chemical and biological properties that are distinct from those of 
bulk materials or single molecules. For example, nanosized particles can provided higher 
bioavailability of drugs because of the increased surface area followed by an increased 
dissolution rate of the drug compounds according to the Noyes-Whitney equation. 
Importantly, nanoparticles with smaller size and proper composition have the potential to 
cross the blood brain barrier (BBB), delivering antiretroviral drugs (ARVs) to the brain, one 
important anatomical reservoir for HIV. 
Nanoformulations that have been used for the delivery of ARV can be roughly divided 
to four categories: drug suspension (nanosuspension), polymer-based nanoformulation, 
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lipid-based nanoformulation and inorganic nanoparticles. Nanosuspensions, also known 
as drug suspension or nanocrystals, are sub-micron colloidal dispersions of pure particles 
of drug, which are stabilized by surfactants13. It is the most promising type of 
nanoformulation that can be used for the development of nanoART. Compared to other 
nanoformulations, the key features of nanosuspensions are the minimal use of excipients 
and the industrially feasibility. The former advantage implies both high drug content and 
diminished excipient-related toxicity. For other nanoformulations, low drug loading, 
potential excipient-related toxicity and manufacturing difficulties have severely 
constrained clinical applications14,15.  
Liposome, the first generation of nanoformulation and one of the most successful drug 
delivery systems, was first described by Bangham and his co-workers in 1961 and the first 
liposomal pharmaceutical product, Doxil®, received clinical approved in 1995. It took more 
than 30 years for the liposomal pharmaceutical products to appear on the market. But it 
was less than 10 years for the first nanosuspension product, Rapamune®, to be available 
on the market after the first patent application of nanosuspension filed in the beginning of 
1990s. Besides those two essential benefits that have been mentioned above, as one type 
of nanoformulation, the sizes of nanosuspensions are usually between 200 to 600 nm, 
which lead to enhanced dissolution, absorption, and bioavailability of drugs. This type of 
naonoformulation has already been widely used for water insoluble drugs. But some 
hydrophilic drugs undergo chemically modification to improve their hydrophobicity can also 
be manufactured using this technique. Besides that, scientists recently developed novel 
solid-in-oil nanosuspensions for hydrophilic drugs. Another prominent advantage of 
nanosuspension is the reduced injection volume as a result of nearly 100% drug loading, 
which is essential for intramuscular (IM), subcutaneous (SC) administration, namely depot 
injections, that allow the nanosuspension to releases its active therapeutic agents in a 
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consistent way over a long period of time to further improve the sustained release profile 
of the drugs. However, it can also be administrated through other routes like oral, topical, 
intravenous, ocular and pulmonary routes16. 
Nanosuspension can be prepared by two basic methods, bottom-up technology and 
top-down technology. Bottom up technology is an assembling method to form 
nanoparticles by precipitation. Top down technology involves the particles size reduction 
of large particles, which comprises high-pressure homogenization and bead/pearl milling 
methods. However, the combination techniques, pre-treatment followed by a size 
reduction step, are also being employed. The ingredients used in the formulation of 
nanosuspension include crystalline active therapeutic agents along with stabilizers 
(surfactants, polymers), tonicity agents (salts, sugars), cryoprotectants and solvents.  
1.6.2 Preparation and characterization of nanoART 
A variety of nanosuspensions17 were prepared for crystalline indinavir (IDV), ritonavir 
(RTV), ATV, and efavirenz (EFV) by wet milling. The influence of the physical 
characteristics of these formulations, including particle size, surfactant coating, surface 
charge and shape, on the cell uptake, release and antiretroviral efficacy were evaluated 
in a monocyte-derived macrophage (MDM) in vitro testing system. It was concluded that 
drug type, surfactant coating, and shape demonstrated profound impact on particle uptake, 
drug release, and antiretroviral activity while particle charge and size only had minor 
effects. For example, it was shown that nanoparticle with longer rod-like shaper were 
taken up more rapidly that short rods and spherical particles were taken up even slowly 
than short rods. 
Several different nanoformulations 18 were manufactured for crystalline IDV, RTV, ATV, 
and EFV by three different methods included wet milling, homogenization and sonication 
using a variety of excipients and the properties of these formulations were compared by 
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using an established MDM scoring indicator system. The results showed that the 
manufacturing methods affected the physicochemical properties of the nanoformulations. 
The IDV nanosuspension were the most diverse with sizes of 252 and 418 nm and charges 
of -40.6 and -15.1 mV, manufactured by wet milling and homogenization respectively, and 
the IDV PLGA nanoparticles prepared by sonication had a size of 367 nm and a charge 
of -9.6 mV. Different preparation methods and excipients also affected the biological, 
immune, virologic, and toxicological properties of these formulations demonstrated by 
mixed results from drug uptake, retention, release, and antiretroviral activity studies. For 
example, in vitro cell uptake study, ATV concentration in cells after 8 hours incubation was 
3- to 4-fold lower following PLGA nanoparticles treatment than that for homogenized or 
milled particles. However, it is shown that the most significant difference affect cell 
targeting and antiretroviral activity of nanoparticles was the drug itself. Based on those 
results, it was proposed that the clinical utility of nanosuspension might depend on the 
choice of drug and formulation composition.  
1.6.3 Subcellular nanoART distribution 
Intracellular trafficking19 of RTV nanosuspension from the point of initial uptake to final 
release in MDM was investigated. It was shown that most nanoparticles taken up by MDM 
through clathrin-dependent endocytosis were sorted into a recycling pathway, from early 
endosome to recycling endosome, while bypassed lysosomal degradation, and drugs 
finally were released intact from MDM without reduction in antiretroviral efficacy. siRNAs 
against Rab8, Rab11, Rab14 and brefeldin-A (BFA), a disruptor of recycling and secretory 
activities, were used to disrupt this pathway. Compared to untreated, siRNA scramble- 
and Rab8 siRNA-treated MDMs, Rab11 and Rab14 siRNA treated cells retained more 
drugs and released fewer drugs into the media. MDM treated with BFA showed similar 
impaired drug release, resulting in aggregation of nanoparticles in the perinuclear region. 
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Proteomic and biological analysis suggested that particle recycling was primarily Rab11 
regulated. Interestingly, it was shown that intact nanoparticles could be released from 
MDM with same size and shape as the original particles and maintained the antiretroviral 
activities. These results suggested the potential and advantages of targeting macrophage 
for cell-based drug delivery. 
A further study20 demonstrated that ATV nanosuspension (nanoATV) enhanced drug 
antiretroviral efficacy by improving the establishment of the subcellular drug depots and 
altering drugs distribution toward sites of active viral replication (Figure 1.3). Late and 
recycling endosome compartments were pull down by immunoaffinity chromatography 
with Rab-specific antibodies conjugated to magnetic beads and ATV nanoparticles were 
seen in these subcellular compartments. It was discovered that nanoATV persisted in 
Rab7+ late endosomal compartments of HIV-1 infected MDMs, the site of active viral 
assembly, while most of nanoparticles stored in Rab11+ recycling endosomes of 
uninfected MDMs. These results were cross validation by immunofluorescent staining of 
these compartments for confocal microscopy. Since infectious HIV-1 released from MDM 
are assembled in late endosomes, such colocalization between HIV and nanoATV in 
subcellular compartments might provide additional benefits in restricting viral replication. 
Thus, it was reasoned that the action of nanoART could be amplified by directing nanoART 
to the late endosomal sites operative for viral assembly21.  
Quantitative SWATH-MS proteomics22 was applied to investigate cellular proteins that 
are deregulated by native ATV or nanoATV with or without HIV-1 infection in MDMs. The 
results showed that HIV-1 and nanoATV engaged endolysosomal trafficking for assembly 
and depot formation, respectively. Compared to virus, nanoATV oppositely regulated 
endolysosomal proteins. For example, in nanoATV-treated HIV-1 infected MDMs, Rab5 
and Rab7 were down-regulated, while up-regulation of these proteins was observed in 
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HIV-1 infected MDMs. DAVID and KEGG bioinformatics were used to analyze the 
proteomic data and the relationships between secretory, mobility and phagocytic cell 
functions and virus and particle trafficking were shown. In this study, a previously unknown 
mechanism for how long-acting nanoART provides a strategic advantage to combat viral 
infection was discovered. 
1.6.4 Cabotegravir (CAB) LA and Rilpivirine (RPV) LA 
GlaxoSminthKline is the leading pharmaceutical company for the development of long-
acting nanoART for HIV treatment and prevention23. They developed a long-acting 
injectable nansuspension that had 200 nm median particle size for Cabotegravir 
(GSK1265744), an integrase inhibitor, by using wet milling technology. They reported that 
in the phase I study of this nanoformulation, following single IM or SC injection, the mean 
plasma level concentration of Cabotegravir remained well above the PA-IC90 for about or 
longer than 24 weeks for dose of at least 200 mg. And Cabotegravir was still detectable 
in plasma up to 48 weeks. Further clinical trials for the evaluation of the safety, tolerability, 
and acceptability of GSK1265744 long-acting injectable formulation (744 LA) in adult male 
subjects is ongoing. Long-acting injectable nanosuspension, called TMC278 LA, for 
rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI) was also 
developed24. The free base of RPV was a stable crystalline polymorphic drug substance 
with very low water solubility. Its nanosuspersions could be easily manufactured by wet 
milling technology. The average particles sizes of nanosuspensions were 200, 400 and 
800 nm and all of them were stable over 6 months. Following single dose administration, 
the plasma concentration profiles showed sustained release of RPV over 3 months in dogs 
and 3 weeks in mice. Compared to 400 and 800 nm nanosuspensions, 200 nm 
nanosuspension achieved higher and more stable plasma concentration profiles, acted as 
long-acting injectable nanoformulation. In a further preclinical investigation25, 200 nm 
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nanosuspension of TMC278 was administered in rats and dogs as single IM or SC 
injection. RPV showed sustained and dose-dependent release over 2 months in rats and 
over 6 months in dogs. In the IM injection groups, the RPV concentrations in the lymph 
nodes exceeded the plasma concentrations by over 100-fold one month after 
administration, then decreased to 3- to 6-fold of the plasma concentrations 3 months after 
administration. It was suggested that such observation was due to the nanoparticle’s 
uptake by macrophages, and then the establishment of secondary depots in lymph nodes. 
In the phase I study of TMC278 LA, single 400 mg and 600 mg doses, administrated 
subcutaneously around the umbilicus or intramuscularly in the gluteus maximus muscle, 
gave prolonged RPV plasma exposure of approximately 20 ng/mL after 8 weeks without 
serious adverse events. The combination uses of 744 LA and TMC278 LA were also 
clinically evaluated. In a phase III clinical trial, the study results showed that the 
combination use of this two LA, injected once a month, had similar efficacy to a standard 
of care, daily, oral three-drug regimen at week 48. 
1.7 Long-acting slow effective release antiretroviral therapy (LASER ART) 
In recent years, LASER ART have been developed in our labs to further improved the 
pharmacokinetics and pharmacodynamics of nanoART26. The main idea of LASER ART 
is modification of ARV to improve the its chemical, physical and biological properties to 
achieve higher drug loading into nanoparticles, slower dissolution rate, longer apparent 
half-lives, better viral reservoir penetration and eventually excellent patient treatment 
adherence. 
1.8  Significance of current projects 
NRTIs served as the “backbone” of antiretroviral drug regimen. Generally, two NRTIs 
are used along with a drug from other classes. But, the dosing frequency of LA reagent is 
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determined by the drug’s aqueous solubility/hydrophobicity, antiretroviral potency/daily 
dose and system clearance/half-life27  which means all the approved NRTIs are not suited 
for redevelopment as long-acting injectable products using conventional pharmaceutical 
manufacturing approaches. For example, the solubility, EC50/daily dose and half-life of 
abacavir (ABC) are 2 mg/ml, 0.07 to 5.8 μM/600 mg (8.6 mg/kg), 1.54 h, while they were 
0.1 mg/ml, 0.22 to 1.3 nM/0.30 mg (0.4 mg/kg), 40 h for CAB. It is worth noting that CBV-
TP, the active triphosphate metabolite of ABC, has half-life of 20 h which supported the 
daily dose of ABC. However, in order to achieve equivalent therapeutic drug exposure for 
LA formulation when compared with daily, oral version of NRTIs, the solubility and antiviral 
potency of NRTIs definitely need to be adjusted in scale of one or two orders of magnitude. 
We have reduced the solubility of ABC by conjugating it with myristoyl chloride (MABC) 
and successfully nanoformulated MABC by high pressure homogenization28. Detectable 
level of ABC was observed during the whole 14-day time period in vivo study, while the 
CBV-TP level was not ideal29. Clearly, the antiretroviral activity of ABC also needs to be 
adjusted. 
In this project, we proposed to combine ProTide technology with our technologies of 
long-acting nanoformulation development to generate second-generation of ABC LA. First, 
we proved that ProTide technology which deliver pre-activated monophosphate of ABC 
into the cells was able to improve the potency of drugs. Second, we demonstrated ProTide 
technology can be used in combination with our technologies for the development of 
second generation of ABC LA. Third, we discussed the optimization of such combination. 
In summary, this project provided a new strategy for the development of NRTIs LA include 




Figure 1.1 Life cycle of HIV (https://aidsinfo.nih.gov/). 
The figure illustrates the main steps in the HIV-1 replication cycle: binding to the CD4 
receptor and co-receptors; fusion with the host cell membrane; uncoating of the viral 
capsid; release of the HIV RNA and proteins into the cytoplasm; reverse transcription of 
HIV RNA to DNA; and translocation into the nucleus. Once inside the nucleus, the viral 
DNA is integrated into the host DNA so HIV can use host cell machinery to make new viral 
RNA and viral proteins that translocated to the cell surface to assemble into new immature 
virus forms. The new viruses bud off and covert to its mature form.   
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Figure 1.2 Metabolic pathway of abacavir (ABC). 
Once inside the cells, ABC is stepwise phosphorylated by intracellular kinases and 
converted to its active metabolite CBV-TP to inhibit the synthesis of viral DNAs.  
Concurrently, it will also be metabolized mainly in liver by UGT and ADH enzymes to its 




Figure 1.3 Intracellular pathway of HIV-1 and nanoATV. 
NanoATV enters MDMs via clathrin-coated pits and is then transported to the early 
endosome. Then most of the nanoparticles are transported to the Rab11+ recycling 
endosome in uninfected MDMs while most of the nanoparticles persisted in Rab7+ late 
endosomal compartments in HIV-1 infected MDMs, the site of active viral assembly. 
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Chapter 2  




Abacavir (ABC) ProTide AlaMe was synthesized based on ProTide technology with 
high yield. The antiretroviral activity (EC50) of AlaC1 was 23.9 nM, when measured in MDM 
against HIV-1ADA and was significantly improved as compared to ABC (161.7 nM). Lipid 
coated PLGA nanoparticle loaded with AlaMe (NAlaMe) was prepared using thin-film 
hydration. The size, PdI, and zeta-potential of NAlaMe measured by Zetasizer was 256 
nm, 0.2 and -51 mV, respectively. Cell uptake and retention study of NAlaMe and AlaMe 
was tested in MDM. In 8 h uptake study, highest uptake of NAlaMe was observed at 8 h 
time point as 2671.1 ng/ml which was 275-fold higher that the uptake of AlaMe. In a 15-
day retention study, for AlaMe free drug treatment group, AlaMe level was under 
detectable level since Day 1, while for NAlaMe treatment group, AlaMe levels were 436.2, 
337.5, 58.0 and 20.3 ng/ml at day 1, 5, 10 and 15 after treatment. The extended retention 
of AlaMe translated to improved antiretroviral efficacy results, NAlaMe was able to protect 
MDM against HIV-1 infection up to Day 10 revealed by both P24 staining and RT assay. 
In vivo pharmacokinetic study showed that NAlaMe was able to provide higher levels of 
CBV-TP in both PBMC and tissues. Pharmacodynamic study of NAlaMe also showed 
certain improvement in antiretroviral activity as compared to ABC. In conclusion, ProTide 
technology was able to improve the drug potency both in vitro and in vivo, and might be 
useful for the development of second-generation ABC LA. 
2.2 Introduction 
NRTIs include ABC need to be activated by a number of nucleoside and nucleotide 
kinases in a stepwise manner resulting in the formation of the mono-, di-, and 
triphosphoralyated nucleoside analogue metabolites to exert their therapeutic effects. 
Factors limit the potency of NRTIs include, but not limit to, their poor affinity to the kinase 
which leads to inefficient formation of the active triphosphate metabolites, and their polarity 
 24 
which leads to low membrane permeability and poor bioavailability. It was proposed that 
delivering phosphorylated metabolites of the NRTIs would addressee some of these 
limitations. 
Numerous prodrug technologies have been proposed to deliver monophosphate into 
the cells. Among them, ProTide technology which developed by Prof. Chris McGuigan 
was a huge success and had led to at least 10 clinical candidates and two FDA-approved 
drugs, TAF1 and sofosbuvir. Remarkably, TAF is 1,000 times more potent than TFV and 
10 time more potent that the prodrug TDF2. 
In this chapter, we discussed the possibility of employing ProTides technology to 
develop second generation of ABC LA. We synthesized ABC ProTides and loaded it into 
lipid coated PLGA nanoparticles (NAlaMe). It’s in vitro and in vivo behaviors were 
investigated. 
2.3 Results 
2.3.1 Synthesis of ABC ProTides 
AlaMe.was successfully synthesized according to ProTide technology (Figure 2.1). 
On a scale of 1 g (3.492 mmol) of ABC, 1.4 g (76 %) of AlaMe product was formed: 1H 
NMR (500 MHz, CD3OD): 7.66 (d, J = 6.6 Hz 1H), 7.10-7.40 (m, 6H), 6.15 (dd, J = 13.7, 
5.7 Hz 1H), 5.97 (br, 1H), 5.53 (br, 1H), 4.08-4.30 (m, 2H), 3.85-4.0 (m, 1H), 3.23 (s, 3H), 
3.21 (br, 1H), 2.93 (br, 1H), 2.81 (td, J = 16.9, 8.3 Hz 1H), 1.65-1.80 (m, 1H), 1.20-1.40 
(m, 4H), 0.85 (app. d, J = 5.8 Hz 2H), 0.62 (br, 2H). 13C NMR (125 MHz, CDCl3): δ 175.4, 
161.7, 157.4, 152.2, 138.1, 137.2, 131.7, 130.6, 126.1, 123.7, 121.4, 114.8, 70.1, 60.5, 
52.7, 51.5, 47.1, 35.4, 24.3, 20.8, 20.5, 14.5, 7.6. 31P NMR (202 MHz, CD3OD); 3.87, 
3.58. MS-ES+ (m/z): calcd. for C24H30N7O5P, 527.20 (100%), 528.21 (26.0%), 529.21 
(2.7%); found, 528.2 [M+H+]. 
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2.3.2 Antiretroviral activity of AlaMe 
Then we measured the antiretroviral activity of AlaMe and ABC in MDM against HIV-
1ADA (Figure 2.2). The antiretroviral activity (EC50) was 23.9 and 161.7 nM for AlaMe and 
ABC, respectively. The EC50 of AlaMe was 7-fold smaller as compared to ABC, which 
means the antiretroviral potency of AlaMe is significant improved by ProTide technology 
as previously reported3. 
2.3.3 Preparation and characterization of NAlaMe 
PLGA nanoparticles have been used to deliver all kinds of drugs include proteins, 
genes and other small molecules, owing to their attractive properties of biodegradability, 
biocompatibility, ease of processing and sustained release4. However, its surface property 
of PLGA nanoparticles limits its cellular membrane permeability, resulting in poor cell 
uptake and efficiency in in vitro experiments. Lipids include synthetic phospholipids can 
be coated on the surface of PLGA nanoparticles through electrostatic attraction and 
hydrophobic interaction and significantly increase the stability, cell uptake and efficiency 
of  nanoparticles5. Lipid coated PLGA nanoparticles loaded with AlaMe were successfully 
prepared by thin-film hydration methods (Figure 2.3A). The Deff, PdI, and zeta-potential 
of NAlaMe measured by Zetasizer was 256 nm, 0.2 and -51 mV, respectively. TEM 
imaging showed the nanoparticle of NAlaMe had spherical shape (Figure 2.3B). The drug 
loading was calculated as 3%. 
2.3.4 Cytotoxicity, uptake and retention of NAlaMe in MDM 
The cytotoxicity of AlaMe and NAlaMe was investigated in MDM using CCK-8 kit and 
ABC was served as a control. No significant cytotoxicity has been observed until 400 μM 
for ABC, AlaMe and NAlaMe (Figure 2.4). Based on the result, 100 μM was selected for 
other cell-based studies. 
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MDM was treated with 100 μM of NAlaMe for 8 h, and AlaMe free drug was used as a 
control. The uptake of NAlaMe was increased rapidly during the first 2 h, and AlaMe level 
was 1987 ng/ml at 2 h (Figure 2.5A). At 8 h, AlaMe level slowly increased to 2671 ng/ml. 
It is possible that the MDM has already be saturated with NAlaMe nanoparticles at the first 
several hours. AlaMe level for free drug treatment group was substantially lower than the 
nanoparticle treatment group with a peak level 22 ng/ml appeared at 2 h. These results 
suggested that lipid coated PLGA nanoparticles can be used to facilitate the delivery of 
ABC ProTides into the MDM.  
In the retention study (Figure 2.5B), we also observed significant difference between 
AlaMe free drug and NAlaMe treatment group. For free drug treatment group, AlaMe level 
was under detectable level since day 1 while for NAlaMe treatment group, AlaMe level 
stayed above the detection level during the whole study. At day 15, the drug level was 20 
ng/ml for NAlaMe treatment group. 
2.3.5 In vitro antiretroviral study 
Next, we wanted to see whether sustained retention of AlaMe in MDM for the NAlaMe 
treatment group will leads to sustained antiretroviral effect. In vitro antiretroviral study was 
conducted in MDM for ABC, AlaMe free drug and NAlaMe.  
Viral breakthrough was observed for ABC treatment group at day 1 (Figure 2.6-2.7). 
For AlaMe free drug treatment group, since AlaMe was more potent as mentioned above, 
total inhibition of viral growth at was observed at day 1. Partial inhibition of viral replication 
was observed for AlaMe free drug treatment group until day 10 as RT assay showed 
significant lower RT activity. For NAlaMe treatment group, total viral growth inhibition was 
observed up to day 10 with partial viral breakthrough at day 15 (24.8% RT activity as 
compared to the positive control). These results suggested that ABC ProTide AlaMe can 
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protected MDM longer that ABC, and loaded AlaMe into lipid-coated PLGA nanoparticles 
further improved this sustained protection effect.  
2.3.6 Pharmacokinetic study of ABC and NAlaMe 
Male BALB/cJ mice were subcutaneously administered 54.3mg/kg ABC equivalent 
dose of ABC or NAlaMe. The CBV-TP levels in PBMC for ABC and NAlaMe were 76.8 
and 93.3, 9.8 and 35.7 and 0.6 and 2.4 fmol/10^6 cells at 2 h, 24 h and 72 h after treatment, 
respectively (Figure 2.8A). The CBV-TP levels for both groups fell below detection level 
(Figure 2.8B-C) at day 7. CBV-TP could also be detected in spleen and lymph nodes 2 h 
after treatment for both groups. For spleen, the CBV-TP levels were 9.2 or 49.6 fmol/10^6 
cells for ABC or NAlaMe, respectively. For lymph nodes, the CBV-TP levels were 0.8 or 
4.6 fmol/10^6 cells for ABC or NAlaMe, respectively. These results showed that NAlaMe 
was able to deliver CBV-TP for a longer period of time. Moreover, higher levels of CBV-
TP were accumulated in spleen and lymph nodes, which suggested that the nanoparticle 
preferably enter lymphatics system and might be beneficial for the ART. 
2.3.7 Pharmacodynamic study of ABC and NAlaMe 
To determine whether the improved PK profile of NAlaMe could translate into improved 
antiretroviral efficacy, NSG mice were reconstituted with human PBL, a single 
subcutaneously injection was administered of ABC or NAlaMe at 54.3mg/kg ABC 
equivalents dose on day 10, followed by challenging with HIV-1ADA on day 11, and 
necropsy 10 days after HIV-1 challenge. Blood and tissues were collected to determine 
CD4/CD8 ratio, HIV-1p24 expression, and viral RNA/DNA. Flow cytometry analysis 
showed that both ABC and NAlaMe treatment protected the animals from HIV-1-induced 
CD4+ T cell loss to certain degree with NAlaMe showed better protection (Figure 2.9A). 
Immunohistochemical analysis revealed that 1/7 animals in the NAlaMe treated group 
were HIV-1p24 negative in spleen, and 1/7 animal only showed negligible infection while 
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HIV-1p24 positive cells were observed in all the ABC treated mice and untreated HIV-1 
control animals (Figure 2.10). In spleen, lung, lymph node, NAlaMe treatment reduced 
viral RNA compared to ABC treatment or HIV-1 positive controls (Figure 2.9B-F). 
2.4 Discussion 
We confirmed that ProTide technology can be used to increase the potency of ABC. It 
was suggested that there are not rate-limiting steps present in either the phosphorylation 
pathway of abacavir or the activation of ABC ProTide. And all the cellular enzymes 
involved in the conversion of ABC ProTide to CBV-TP (i.e., carboxylesterase(s), 
phosphoramidase, ABC-MP deaminase, and the nucleotide kinases such as CMP kinase 
and NDP kinase) are not metabolically saturated when extracellular drug concentrations 
are as high as 100 μl. This means that increasing cellular delivery of higher ABC-MP 
concentration through ProTide technology will concomitantly result in higher eventual 
CBV-TP6. Indeed, AlaMe and NAlaMe showed improvement in in vitro antiretroviral study 
and NAlaMe showed improvement in both pharmacokinetic and pharmacodynamic profile 
as compared to ABC. Based on these results, we concluded that ProTide technology can 
be used as a part of LASER ART for the development of LA formulation. 
The limitations are, first, the low drug loading of lipid coated PLGA nanoparticle which 
means large amounts of polymers need to be administrated along with the drugs which 
might intensify local inflammation and is hard to achieve industrial production scale. 
Second, because of the comparable hydrophilicity properties of AlaMe, it was quickly 
released from PLGA nanoparticles and CBV-TP level could not be detected after day 3 




Reagents were obtained from commercial sources and used directly; exceptions are 
noted. Abacavir was purchased from BOC Sciences Inc. (Shirley, NY). Phenyl 
dichlorophosphate, L-alanine methyl ester hydrochloride salt, dichloromethane (CH2Cl2), 
chloroform (CHCl3), triethylamine (Et3N), diethyl ether, tetrahydrofuran (THF), tert-
butylmagnesium chloride solution (tert-BuMgCl, 1.0 M in THF), methanol  and poly (D, L-
lactide-co-glycolide; lactide:glycolide (75:25), mol wt 66,000-107,000) (PLGA) were 
purchased from Sigma-Aldrich (St. Louis, MO). Distearoyl-phosphatidylethanolamine-
methyl-polyethylene glycol conjugate-2000 (DSPE-mPEG2k), 1, 2-distearoyl-sn-glycero-3-
phosphocholine (DSPC) and 1, 2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG) were 
purchased from Corden Pharma (Cambridge, MA). Flash chromatography was performed 
using flash silica gel (32-63 μ) from SiliCycle Inc. (Quebec, Canada). Chemical reactions 
were analyzed by thin layer chromatography (T.L.C) on precoated silica plates (200 μm, 
F-254) from Sorbtech technologies Inc. (Norcross, GA). The compounds were visualized 
by UV fluorescence.  
2.5.2 Synthesis and chemicophysical characterization of ABC ProTide 
All chemical synthesis reactions were performed under a dry argon atmosphere unless 
otherwise noted. ABC ProTide AlaMe was synthezied as previously reported3. Briefly, L-
alanine methyl ester (1 mol equiv) and phenyl dichlorophosphate (1 mol equiv) were 
suspended in anhydrous CH2Cl2 (15 mL) and cooled to -78°C in a dry ice/ acetone bath. 
To this mixture, a pre-cooled (-78°C) solution of anhydrous trimethylamine (2 mol equiv) 
in CH2Cl2 was added drop-wise, and the resultant solution was stirred and gradually 
warmed to room temperature over 32 h under an inert argon atmosphere. The reaction 
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mixture was concentrated on a rotary evaporator to yield a white/yellow solid that was 
suspended into diethyl ether and filtered. The filtrate was concentrated to give aryl 
aminoacyl phosphochloridate that was used in the next coupling step without further 
purification. ABC (1 mol equiv) was dried by azeotroping from anhydrous pyridine, then 
suspended in anhydrous THF and cooled to -78 °C under an argon atmosphere. tert-
BuMgCl (2 mol equiv, 1.0 M solution in THF) was added drop wise to the ABC suspension 
and the reaction mixture allowed to stir for an additional 10 min with cooling. A solution of 
aminoacyl phosphorochloridate (1.5 mol equiv) in THF was then added dropwise and the 
resulting mixture was gradually warmed to room temperature and stirred for 48-90 h. The 
reaction mixture was then cooled to 0 °C, quenched with aqueous saturated ammonium 
chloride solution or methanol, concentrated, and the desired ABC ProTides isolated by 
flash column chromatography on silica gel eluting with 95%-90% CH2Cl2/CH3OH mobile 
phase. 
NMR spectra were recorded on a Bruker Avance-III HD (Billerica, MA) operating at 
500 MHz, a magnetic field strength of 11.7T. Proton NMR data is reported in ppm 
downfield from TMS as an internal standard. FT-IR spectra were recorded on a Perkin-
Elmer-spectrum attenuated total reflectance (ATR)-FTIR equipped with a UATR-
accessary (Perkin-Elmer, Inc., Waltham, MA, USA). Mass spectra were obtained on a 
Waters Xevo TQ-S micro triple quadrupole mass spectrometer (Waters, Milford, MA, USA). 
Prodrug quantitation was performed on a Waters Breeze HPLC system (Waters, Milford, 
MA, USA) using a Kinetex 5 µ C18 100A Phenomenex column. For AlaMe, the mobile 
phase consisted of 10 mM potassium phosphate monobasic buffer solution (10 mM 
KH2PO4) and acetonitrile (ACN) with a ratio of 65/35, v/v was at a flow rate of 1 mL/min. 
The retention time was 3.8 min. 
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2.5.3 Cell model for in vitro studies 
Human peripheral blood monocytes were obtained and cultured as previously 
described7. Briefly, human peripheral blood monocytes were obtained by leukapheresis 
from HIV-1/2 and hepatitis B seronegative donors, followed by purification via 
countercurrent centrifugal elutriation. Elutriated monocytes were cultured as adherent 
cells in Dulbecco’s mimimum essential medium (DMEM) supplemented with 10% heat-
inactivated pooled human serum, 10 μg/mL ciprofloxacin, 50 μg/mL gentamicin, and 1000 
U/mL recombinant macrophage colony stimulating factor. Cells were maintained at 37 °C 
in a 5% CO2 incubator. Seven days later, differentiated macrophages (MDM) were used 
for the experiments. 
2.5.4 Antiretroviral activity of ABC and AlaMe 
The antiviral activities of native ABC and AlaMe against HIV-1ADA were determined in 
MDM as previously described8. MDM were incubated with various concentrations of ABC 
or AlaMe for 60 min followed by infection with HIV-1ADA at a multiplicity of infection (MOI) 
of 0.01 for 4 h. The MDM were washed extensively with phosphate buffered saline (PBS) 
to remove excess virus particles. The cells were incubated an additional 10 days in the 
presence of the same concentration of drug used before infection. Cell culture medium 
was changed every other day with replacement of equivalent drug containing media. At 
day 10 post infection, supernatants were collected and analyzed for HIV-1 reverse 
transcriptase (RT) activity 9. 
2.5.5 Preparation and characterization of NAlaMe 
NAlaMe were prepared using a modified thin film hydration technique as described 
previously10. Briefly, a mixture of lipids consisting of DSPC, DSPE-PEG2k and DSPG in 
10:5:1 weight ratio was coated over drug loaded PLGA nanoparticles to enable sustained 
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release of the loaded cargo. Lipids were dissolved in chloroform first and the organic 
solvent was carefully removed under vacuum to make sure a thin lipid film was form in a 
round-bottom flask. Then lipids were dispersed in 10 mM phosphate buffer (PB) to form 
the aqueous phase. PLGA and AlaMe were dissolved in DCM to form the oil phase. A 
2:1:1 weight ratio of PLGA to drug to lipid shell was used. The oil phase was added into 
the water phase dropwise under gentle stirring. The mixture was vortexed then sonicated 
by probe ultrasonicator under ice bath. DCM then was evaporated and the suspension 
was centrifuged at 14,000 rpm for 10 min at 4℃ to collect the nanoparticle. Effective 
diameter (Deff), PdI, and ζ-potential were measured by dynamic light scattering (DLS) 
(Malvern Zetasizer Nano Series Nano-ZS, Malvern Instruments, Westborough, MA, 
USA). TEM were used to observe the morphology of NAlaMe. 
2.5.6 Cytotoxicity of ABC, AlaMe and NAlaMe 
A CCK-8 Kit was purchased from Dojindo and used to test cell viability after treatment 
with ABC, AlaMe and NAlaMe. Briefly, MDM plated in a 96-well plate were treated with 
100 μl of 0-400 µM ABC, AlaMe and NAlaMe for 24 h. Drug containing medium was 
removed and replaced with fresh medium. Ten μl of CCK-8 solution was added to each 
well followed by incubation of the plate for 2 h at 37˚C. The absorbance (at 450 nm) of 
each well was measured using a microplate reader. The cell viability was calculated 
according to manufacturer’s instructions. 
2.5.7 Cell uptake and retention of AlaMe and NAlaMe 
Uptake and retention of nanoformulations were determined in MDM as previously 
reported8,11-14. Briefly, MDM were treated with different nanoformulations at a 
concentration of 100 µM for 1, 2, 4 and 8 h. At select time points, adherent MDM were 
collected in 1 mL PBS after washing with 1 mL PBS twice.  MDM were pelleted by 
centrifugation at 3,000 rpm for 8 min. The cell pellet was reconstituted in 200 µl methanol 
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and probe sonication (10 sec) was used to break the cells and extract drugs. After probe 
sonication, cell debris was pelleted by centrifugation at 14,000 rpm for 10 min and 4˚C. 
The supernatant was analyzed for prodrug level using HPLC-UV/Vis. For retention, MDM 
were treated with 100 µM different nanoformulations for 8 h. The nanoformulation-
containing media were replaced with fresh media after washing MDM with PBS twice. At 
days 1, 5, 10, and 15, MDM were collected in 1mL PBS after washing with 1 mL PBS 
twice. The samples were processed as described above for analysis using HPLC.  
2.5.8 Antiretroviral efficacy 
Antiretroviral efficacies of ABC, AlaMe and NAlaMe in MDM were assessed as 
previously described8. MDM were incubated with 100 µM different treatment for 8 h. Then 
drug-containing medium was replaced with fresh medium after washing MDM with PBS 
twice. Half media changes were conducted every other day. At predetermined time points, 
day 1, 5 ,10, and 15, MDM were infected with HIV-1ADA for 4 h at a MOI of 0.1 and cultured 
with every-other-day half media changes for an additional 10 days. At day 10, supernatant 
was collected for RT assay and MDM were fixed with paraformaldehyde and 
immunostained for expression of HIVp24. Untreated, uninfected MDM served as negative 
(control), while MDM exposed to HIV-1ADA but not treated with drugs, served as positive 
controls (HIV-1).  
2.5.9 Pharmacokinetic study of ABC and NAlaMe 
Male BALB/cJ mice (Jackson Labs, Bar Harbor, ME, USA) were administrated 
subcutaneously with ABC or NAlaMe at 54.3 mg/kg ABC equivalent dose. At 2h, day 1, 3 
and 7, three mice from each group were sacrificed, and blood, spleen and lymph nodes 
(pooled) were collected as previously reported before. Specifically, bloods were collected 
in EDTA tubes and PBMCs were separated using Histopaque-1083 (Sigma Chemical Co. 
St. Louis, MO; Catalog # 1083-1) according to the manufacturer’s instruction. Separated 
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PBMCs were centrifuged (400 g for 10 min), resuspended in 200 μl of 70% methanol and 
stored in −20 °C until sample preparation for CBV-TP measurement. Spleens were 
collected, minced into small pieces using scalpel blades, and transferred to 70 μm nylon 
cell strainers (BD Falcon # 352350) inserted into the top of 50-ml conical tubes. 5 ml of 
HBSS was added in total and single cells were forced to pass through strainers. Cell were 
pelleted by centrifugation at 200g for 10 min, and supernatants were discarded. The 
resulting cell pellets were resuspended in one ml of RBC lysing buffer (ACK buffer), 
incubated for two minutes at 37 °C, neutralized with 14 ml of HBSS, centrifuged at 200g 
for 10 min, supernatants were discarded, and cell pellets underwent one more cycle of 
washing and centrifugation. The resulting cell pellet was resuspended in 2 ml PBS and 
counted with a hemocytometer. Finally, cells were centrifuged at 400 g for 10 min and cell 
pellet was lysed with 200 μl of cold 70% MeOH for CBV-TP sample extraction. For lymph 
node lymphocyte preparation, freshly removed lymph nodes from all three mice were 
pooled (∼15–18 lymph nodes) for every time-point, and cells were isolated similarly to 
splenocytes as described above, except that the RBC lysis step was not used. 
2.5.10 Pharmacodynamics study of ABC and NAlaMe 
Male 6-8-week-old NOD/scid-IL-2Rγcnull (NSG) mice (Jackson Labs, Bar Harbor, ME, 
USA) were reconstituted by intraperitoneal injection with 25 × 106 human peripheral blood 
lymphocytes (PBL) obtained by leukapheresis and centrifugal elutriation. 10 days after 
reconstitution, mice were injected subcutaneously with ABC or NAlaMe at 54.3 mg/kg ABC 
equivalent dose. 11 days after reconstitution, mice were challenged with 104 50% tissue 
culture infectious dose (TCID50) HIV-1ADA by intraperitoneal (IP) injections. Mice were 
sacrificed 10 days after viral challenge. Blood were collected 1 day before and 10 days 
after viral challenge for flow cytometry analysis of human pan-CD45, CD3, CD4 and CD8 
immune markers15. Tissues were also collected at the sacrifice day for viral RNA and DNA 
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quantitation by semi-nested real-time PCR16, and immunohistochemical staining for HIV-





Figure 2.1 Synthesis scheme of AlaMe. 
Reagent and condition: a. Phenyl dichlorophosphate, Et
3
N, CH2Cl2, -78 ℃-rt, 16 h. 




Figure 2.2 EC50 of ABC and AlaMe in MDM against HIV-1ADA. 
MDM were incubated with various concentrations of ABC or AlaMe for 60 min followed 
by infection with HIV-1ADA at a multiplicity of infection (MOI) of 0.01 for 4 hr. The MDM 
were washed extensively with phosphate buffered saline (PBS) to remove excess virus 
particles. The cells were incubated an additional 10 days in the presence of the same 
concentration of drug used before infection. Cell culture medium was changed every other 
day with replacement of equivalent drug containing media. At day 10 post infection, 
supernatants were collected and analyzed for HIV-1 reverse transcriptase (RT) activity 9. 
The EC50 of ABC or AlaMe is 161.7 or 23.9 nM, respectively. 
  






















Figure 2.3 Preparation and characterization of NAlaMe. 
A. Scheme of NAlaMe preparation. Briefly, a mixture of lipids consisting of DSPC, 
DSPE-PEG2k and DSPG in 10:5:1 weight ratio was coated over drug loaded PLGA 
nanoparticles to enable sustained release of the loaded cargo. Lipids were dissolved in 
chloroform first and the organic solvent was carefully removed under vacuum to make 
sure a thin lipid film was form in a round-bottom flask. Then lipids were dispersed in 10 
mM phosphate buffer (PB) to form the aqueous phase. PLGA and AlaMe were dissolved 
in DCM to form the oil phase. A 2:1:1 weight ratio of PLGA to drug to lipid shell was used. 
The oil phase was added into the water phase dropwise under gentle stirring. The mixture 
was vortexed then sonicated by probe ultrasonicator under ice bath. DCM then was 
evaporated, and the suspension was centrifuged at 14,000 rpm for 10 min at 4℃ to collect 











Figure 2.4 Cytotoxicity of ABC, AlaMe and NAlaMe. 
MDM plated in a 96-well plate were treated with 100 μl of 0-400 µM ABC, AlaMe and 
LNAlaMe for 24 hr. Drug containing medium was removed and replaced with fresh 
medium. Ten μl of CCK-8 solution was added to each well followed by incubation of the 
plate for 2 hr at 37˚C. The absorbance (at 450 nm) of each well was measured using a 





Figure 2.5 Cell uptake and retention of AlaMe and NAlaMe in MDM. 
A. Uptake study. MDM were treated with different nanoformulations at a 
concentration of 100 µM for 1, 2, 4 and 8 h. At select time points, adherent MDM were 
collected in 1 mL PBS, pelleted by centrifugation at 3,000 rpm for 8 min. The cell pellet 
was reconstituted in 200 µl methanol and analyzed by HPLC. B. Retention study, MDM 
were treated with 100 µM different nanoformulations for 8 h. The nanoformulation-
containing media were replaced with fresh media after washing MDM with PBS twice. At 
days 1, 5, 10, and 15, MDM were collected in 1mL PBS after washing with 1 mL PBS 




Figure 2.6 p24 staining of MDM for antiretroviral study. 
MDM were incubated with 100 µM different treatment for 8 h. Then drug-containing 
medium was replaced with fresh medium after washing MDM with PBS twice. Half media 
changes were conducted every other day. At predetermined time points, day 1, 5 ,10, and 
15, MDM were infected with HIV-1ADA for 4 h at a MOI of 0.1 and cultured with every-other-
day half media changes for an additional 10 days. At day 10 after infection, MDM were 
fixed with paraformaldehyde and immunostained for expression of HIVp24. Untreated, 
uninfected MDM served as negative control (control), while MDM exposed to HIV-1ADA but 




Figure 2.7 RT assay result of MDM for antiretroviral study. 
MDM were incubated with 100 µM different treatment for 8 h. Then drug-containing 
medium was replaced with fresh medium after washing MDM with PBS twice. Half media 
changes were conducted every other day. At predetermined time points, day 1, 5 ,10, and 
15, MDM were infected with HIV-1ADA for 4 h at a MOI of 0.1 and cultured with every-other-
day half media changes for an additional 10 days. At day 10 after infection, media were 
collected for RT assay. Untreated, uninfected MDM served as negative control (control), 





Figure 2.8 Pharmacokinetic results of ABC and NAlaMe. 
CBV-TP level in PBMC separated from blood samples (A), and cells separated 
from spleen (B) and lymph nodes (C). Male BALB/cJ mice were injected 
subcutaneously with ABC or NAlaMe at 54.3 mg/kg ABC equivalent dose. At 2 h, day 1, 
3 and 7, three mice from each group were sacrificed, and blood, spleen and lymph nodes 
(pooled) were collected. PBMC or cells are separated from blood, spleen and lymph nodes. 




Figure 2.9 Comparison of antiretroviral activities of ABC and NAlaMe in hu-PBL 
reconstituted NSG mice infected with HIV-1. 
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Male NOD/scid-IL-2Rγcnull (NSG) mice were reconstituted by IP injection with 25 × 106 
human peripheral blood lymphocytes (PBL) obtained by leukapheresis and centrifugal 
elutriation. 10 days after reconstitution, mice were injected subcutaneously with ABC or 
NAlaMe at 54.3 mg/ka ABC equivalent dose. 11 days after reconstitution, mice were 
challenged with 104 50% tissue culture infectious dose (TCID50) HIV-1ADA by IP injections. 
Mice were sacrificed 10 days after viral challenge. Blood were collected 1 day before and 
10 days after viral challenge for flow cytometry analysis of human pan-CD45, CD3, CD4 
and CD8 immune markers (A). Tissues were collected at the sacrifice day for viral RNA 




Figure 2.10 Levels of HIV-1p24 antigen in liver and spleen of HIV-1 infected 
huPBL-reconstituted NSG mice treated with ABC and NAlaMe. 
Spleens were collected on sacrifice day, then sectioned and immunostained with 
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Chapter 3  




The entry of LA formulation into clinical practice can broaden current available 
therapeutic approaches for treatment of HIV infection. LA serves to facilitate ARV HIV 
reservoir delivery while improving patient adherence and reducing viral resistance and 
drug toxicity. In works to develop a library of LA formulations, ABC, a NRTIs and a 
component of a first line HIV treatment was modified by ProTide technology to increase 
its potency. Three ABC ProTides (AlaMe, PheMe and PheC22) were synthesized. The 
hydrophobicity produced by a fatty alcohol moiety of PheC22 further enhanced its 
apparent half-life. A single treatment of human monocyte derived macrophages with 
PheC22 nanoformulations led to sustained intracellular carbovir-triphosphate (CBV-TP) 
and potent antiretroviral activity for up to 30 days.  
3.2 Introduction 
The translation of LA formulation from laboratory research into clinical practice could 
improve HIV prevention and treatment and inevitably speed viral eradication efforts. The 
advantages of LA formulation over other antiretroviral regimens are defined by high ARV 
penetrance into cell and tissue viral reservoirs and infrequent dosing requirements. Both 
affect treatment outcomes by maximally suppressing viral growth through facilitated ARV 
entry into viral target cells1,2. Regimen adherence can be improved by reducing the dosing 
frequency. But only a few FDA approved ARVs have the right properties for LA formulation. 
The development of LASER ART technology that can modify the chemical, physical and 
biological properties of ARVs allowed LA formulation to be developed for more ARVs. 
Indeed, recent data from our laboratories demonstrate that conversion of existing ARVs 
into prodrugs extend their apparent half-lives and reduce systemic drug toxicities3-6. 
However, while prodrugs represent > 10% of all small molecules approved for human use, 
few entered into HIV treatment regimens and none have appeared as part of long-acting 
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ARV therapies7. Nonetheless, their advantages in facilitating drug biodistribution and 
extending drug half-lives is already known8.   
Herein，ABC ProTide LA were successfully developed by ProTide technology. While 
the idea was first introduced more than two and a half decades ago, the application of 
ProTide technology to ABC has focused on improving drug potency9,10 not in extending its 
apparent half-life or in affecting viral reservoir biodistribution. To these ends, we 
implemented strategies to mask parent drug monophosphates with cleavable hydrophobic 
lipid creating ProTides that demonstrated improved plasma drug stability, membrane 
penetration and encapsulation. The synthesis and antiretroviral profiles of three ABC 
ProTides are described. One, PheC22 was defined by efficient encasement into 
nanoparticles, production of high intracellular CBV-TP metabolites and superior 
monocyte-macrophage depot formation that enhanced antiretroviral activities. 
3.3 Results 
3.3.1 Synthesis of ABC ProTides 
Prior works demonstrated that L–alanine and L-phenylalanine ester 
phosphoramidates provide potent ProTides10,11. Thus, we created AlaMe and PheMe 
bearing alanine and phenylalanine methyl ester residues. PheC22 was synthesized by 
substituting the methyl ester in PheMe for a docosyl ester promoiety. A docosanol masking 
ester motif was selected based on its lipophilicity, antiviral activities and inherent 
synergistic effect on nucleoside analogs12,13. ProTide hydrolysis was reasoned to release 
two pharmacophores that inhibit viral reverse transcriptase activity14. We reasoned that 
improving ABC physicochemical features would facilitate nanoformulation preparation, 
enhance intracellular ABC levels and extend the drugs’ apparent half-life. The first step in 
the synthesis of ABC ProTides required preparation of aryl amino ester 
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phosphorochloridates from appropriate amino acid esters and commercially available 
phenyl phosphorodichloridate15. Phenylalanine and alanine methyl esters were purchased 
while phenylalanine docosyl ester was prepared according to step 1 of Figure 3.1. The 
aryl amino ester phosphorochloridates were then synthesized by coupling phenyl 
phosphorodichloridates to amino acid esters in the presence of triethylamine (Figure 3.1 
Step 2)10. Each of the amino ester phosphorochloridate was then reacted with ABC in the 
presence of tert-BuMgCl and purified by flash column chromatography. This generated 
high yields of AlaMe, PheMe and PheC22. Successful synthesis of ABC ProTides was 
confirmed by 1H, 13C and 31P NMR spectra (Figure 3.2-3.5). As previously reported for 
similar compounds, splitting of peaks in the spectra of ProTides was associated with co-
existence of two stereoisomers at the phosphorus atom16. 
3.3.2 Antiretroviral activity of ABC ProTides 
We next evaluated the ProTides for antiretroviral activity. As shown in (Figure 3.6B), 
AlaMe, PheMe and PheC22 exhibited 6- to 200- fold increase in antiretroviral activity over 
ABC in human monocyte-derived macrophages (MDM). PheMe demonstrated the lowest 
EC50 of 0.2 nM. The EC50 of AlaMe and PheC22 were 1.8 nM and 7.0 nM, respectively. 
The differences were likely linked to higher prodrug uptake and metabolism of PheMe to 
form CBV-TP in MDM17. Activation of ABC ProTides require intracellular processing to 
generate CBV-TP10. To better explain the differences in EC50 between native ProTides 
and ABC, MDM were exposed to equivalent concentrations of ABC, AlaMe, PheMe or 
PheC22 followed by quantitation of CBV-TP levels at multiple time points. As shown in 
Figure 3.6C, maximum CBV-TP levels for ABC, AlaMe, PheMe and PheC22 were 177, 
35650, 33135 and 541 fmol/million cells, respectively. At 48 h, CBV-TP levels were 33, 
789, 5025 and 230 fmol/million cells for ABC, AlaMe, PheMe and PheC22. The differences 
in active metabolite levels further suggest that the three ProTides are rapidly taken up by 
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MDM but metabolized at rates dependent on amino acid ester hydrolysis. Notably, at 48 
h, CBV-TP levels for PheC22 declined only by 57% compared to 81, 97 and 84% in the 
amount of active metabolite for ABC, AlaMe and PheMe. We posit that enhanced 
lipophilicity and slower hydrolysis of PheC22 provides controlled and extended release of 
CBV-TP. 
3.3.3 Cytotoxicity of ABC ProTides. 
As intracellular nucleoside triphosphate levels have been implicated in drug toxicities18, 
we assessed mitochondrial dehydrogenase activity of the ProTides using CCK-8 assay. 
As shown in Figure 3.6D, neither ABC, AlaMe, PheMe nor PheC22 affected cell viability 
at drug concentrations of up to 300 µM. However, differences in mitochondrial activity 
were seen at 400 µM with AlaMe and PheMe compared to ABC. No significant differences 
were observed between PheC22 and ABC across all tested drug concentrations. These 
data indicated that the sustained release of effective inhibitory concentration of CBV-TP 
from PheC22 was not detrimental to cell viability and suggested that PheC22 could be 
translated for human use. Previous studies have shown that in vivo accumulation of 
nucleoside triphosphates inside cells could be facilitated by prodrugs that exhibit greater 
stability in plasma19,20. 
3.3.4 Serum stability of ABC ProTides 
To evaluate prodrug stability, we incubated three ProTides in human serum. After 24 
h, > 60% of AlaMe and PheMe were hydrolyzed. Nineteen percent of PheC22, in contrast, 
was degraded after 24 h.  
3.3.5 Preparation and characterization of nanoformulations for ABC ProTides. 
LASER ART was developed, in our laboratories, to improve therapeutic and 
prophylactic outcomes for HIV/AIDS. In the first phase this was accomplished by 
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formulating myristoylated prodrugs encased in a poloxamer surfactant3-6. For ABC, such 
modifications provided only low levels of CBV-TP for less than two weeks5,21. We reasoned 
that ABC ProTide nanoformulations would produce higher levels of intracellular CBV-TP 
at substantially reduced dosing frequency. The less hydrophobic AlaMe was encapsulated 
into lipid-coated poly lactic-co-glycolic acid (PLGA) nanoparticles (NAlaMe) by a modified 
single emulsion solvent evaporation method while hydrophobic and lipophilic PheMe and 
PheC22 ProTides were stabilized into poloxamer coated drug nanoparticles (NPheMe and 
NPheC22) by high-pressure homogenization22-24. The directive of both schemes was to 
produce controlled release drug delivery systems. Drug loading for NAlaMe, NPheMe and 
NPheC22 nanoparticles were 3, 43, and 47%, respectively, underlying the differences 
between PLGA and poloxamer drug encasement systems. Indeed, unlike high-pressure 
homogenization that produces nanoparticles stabilized by surfactants with high drug 
loading, PLGA nanoparticles exhibit low drug loading22,25. Effective diameter (Deff), PdI, 
and ζ-potential were determined by dynamic light scattering (DLS) (Table 3.1) while 
transmission electron microscopy (TEM) assessed nanoparticle morphologies (Figure 
3.7). Nanoparticle morphologies for NAlaMe and NPheC22were spherical with particle 
sizes of 135 nm and 230 nm, respectively, while NPheMe particles were rod-shaped with 
a size of 265 nm. Importantly, high drug loading in NPheMe and NPheC22 
nanoformulations can translate into reduced dosage volumes and minimal injection site 
reactions24. 
3.3.6 Uptake and retention study in MDM for nanoformulated ABC ProTides 
LASER ART has been shown to improve ART pharmacokinetics and 
pharmacodynamics by facilitating cell and tissue drug depots in the reticuloendothelial 
system26-28. Macrophages are outstanding targets for LASER ART due to their large 
storage capacity, high mobility that allows entry to sites of infection and inflammation, and 
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their role as viral reservoirs29,30. To affirm such observations, NAlaMe, NPheMe and 
NPheC22 were administered to MDM at concentrations of 100 μM. Intracellular prodrug 
concentrations were subsequently evaluated over 8 h. As shown in Figure 3.8A, the 
highest drug nanoparticle MDM uptake was observed with NPheC22. At 8 h, intracellular 
prodrug concentration for NPheC22 was 118.5 nmol/106 cells, a 56- and 108-fold higher 
concentration than that observed for NAlaMe (2.1 nmol/106 cells) or NPheMe (1.1 
nmol/106 cells), respectively. Visualization of nanoparticles within MDM by TEM revealed 
greater accumulation of NPheC22 nanoparticles in the cytoplasmic vesicles compared to 
NAlaMe and NPheMe (Figure 3.8E). These observations likely reflect nanoparticle 
stability31,32. To further confirm release of ProTides from nanoparticles and conversion to 
active metabolites, we quantified intracellular CBV-TP levels in MDM after a single 
exposure of ABC, NAlaMe, NPheMe or NPheC22. As shown in Figure 3.8B, CBV-TP 
levels for ABC increased over time and peaked at 4 h (811 fmol/106 cells) before declining 
by 37% (510 fmol/106 cells) at 8 h. For NAlaMe, maximum CBV-TP levels were observed 
at 8 h (39,533 fmol/106 cells) while NPheMe displayed the highest CBV-TP concentration 
of 39,015 fmol/106 cells at 4 h followed by a 43% decrease (22,274 fmol/106 cells) at 8 h. 
Even though lower concentrations of CBV-TP were measured for NPheC22 compared to 
NAlaMe or NPheMe, the active metabolite levels were sustained over 8 h, ranging from 
4,626 to 8,601 fmol/106 cells versus 215 and 811 fmol/106 cells for ABC. Conversion of 
PheC22 to CBV-TP demonstrates sustained drug release and could lead to improved 
patient adherence to therapeutic ARVs33-35. Studies amongst HIV-1 infected patients have 
revealed preferences for long acting ART36. To explore the potential of ProTide 
formulations to extend ABC apparent half-life, MDM were exposed to formulations for 8 h. 
Intracellular ProTide and CBV-TP levels were measured over a 30-day time period. As 
shown in Figure 3.8C, the amount of ProTide retained by MDM was not detected for 
NAlaMe and NPheMe, while NPheC22 exhibited drug concentrations of 95.3 and 48.5 
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nmol/106 cells at days 1 and 30. The retention of CBV-TP in MDM (Figure 3.8D) was 
sustained until day 30 for NAlaMe, NPheMe and NPheC22 but only detected to day 5 for 
ABC. Notably, a single treatment of MDM with NPheC22 provided steady and sustained 
CBV-TP levels greater than 100 fmol/106 cells over the entire 30-day period. Such 
sustained release formulations could minimize variant pharmacokinetic profiles and 
maintain effective drug concentrations at cellular and tissue reservoirs of infection. 
3.3.7 In vitro antiretroviral efficacy of nanoformulated ABC ProTides 
To determine whether sustained intracellular CBV-TP from ProTide formulations 
would translate into improved antiretroviral activity, MDM were challenged with HIV-1ADA 
for up to 30 days after a single 8 h treatment with 100 µM of ABC equivalent. HIV-1 reverse 
transcriptase (RT) activity and p24 antigen expression were assessed in infectious 
supernatants and adherent MDM on day 10 post-infection. As shown in Figure 3.9A and 
3.9C, complete viral inhibition was observed for up to 15 days for NAlaMe. At day 20, 91% 
viral inhibition was recorded that gradually decreased to 83% inhibition at day 30. HIV-
1p24 antigen staining showed that NPheMe protected MDM from infection with viral 
breakthrough at day 30. Of significance, full viral inhibition was observed for 30 days after 
treatment with NPheC22. In contrast, minimal protection against viral infection was 
observed with native ABC at all time points. Comparisons of antiviral efficacy of NPheC22 
were then assessed to determine the lowest drug concentration required for long-term 
MDM protection against viral infection. As shown in Figure 3.9B and 3.9D, 50 µM 
NPheC22 afforded complete viral inhibition for up to 30 days, while a single 8 h treatment 
with 25 µM or 10 µM NPheC22 inhibited viral replication by greater than 90% at day 30 
post drug treatment. These results paralleled prolonged high intracellular CBV-TP levels 
for NPheC22 compared to ABC, NAlaMe or NPheMe. 
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3.3.8 Pilot pharmacokinetic study. 
A pilot in vivo study in rats was conducted with NPheC22. Peripheral blood 
mononuclear cells were recovered from whole blood and intracellular CBV-TP levels 
measured up to day 7. Reduced CBV-TP levels might be explained, in part, by the rapid 
degradation of ProTides or slow cleavage of phosphoramide intermediates in rodents that 
precedes triphosphate formation 37,38.  
3.4 Discussion 
We posit that LA formulation can overcome challenges of ARV adherence and 
biodistribution. In support of this idea, AlaMe, PheMe and PheC22 ProTides were 
synthesized. NPheC22 nanoparticles exhibited improved MDM drug uptake, sustained 
retention and antiretroviral activities for up to one month. We posit that this work is a 
significant step forward for the management and prevention of HIV-1 infection. 
3.5 Methods 
3.5.1 Reagents 
All chemical synthesis reactions were performed under a dry argon atmosphere unless 
otherwise noted. Reagents were obtained from commercial sources and used directly; 
exceptions are noted. Abacavir (ABC) was purchased from BOC Sciences Inc. (Shirley, 
NY). Phenyl dichlorophosphate, L-alanine methyl ester hydrochloride salt, L-
phenylalanine methyl ester hydrochloride salt, N-(carbobenzyloxy)-L-phenylaline, 
docosanol, dichloromethane (CH2Cl2), chloroform (CHCl3), N,N-dimethylformamide (DMF), 
triethylamine (Et
3
N), diethyl ether, tetrahydrofuran (THF), tert-Butylmagnesium chloride 
solution (tert-BuMgCl, 1.0M in THF), triethylsilane (Et
3
SiH), methanol  and poly (D, L-
lactide-co-glycolide; lactide:glycolide (75:25), mol wt 66,000-107,000) (PLGA) were 
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purchased from Sigma-Aldrich (St. Louis, MO). Distearoyl-phosphatidylethanolamine-
methyl-polyethylene glycol conjugate-2000 (DSPE-mPEG2k), 1, 2-distearoyl-sn-glycero-3-
phosphocholine (DSPC) and 1, 2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG) were 
purchased from Corden Pharma (Cambridge, MA). 1-[Bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b] pyridinium 3-oxid hexafluorophosphate (HATU) was obtained from 
Bachem Inc. (Torrance, CA) while palladium, 10% on activated carbon, was purchased 
from STREM Inc. (Newburyport, MA). Flash chromatography was performed using flash 
silica gel (32-63 μ) from SiliCycle Inc. (Quebec, Canada). Chemical reactions were 
analyzed by thin layer chromatography (T.L.C) on precoated silica plates (200 μm, F-254) 
from Sorbtech technologies Inc. (Norcross, GA). The compounds were visualized by UV 
fluorescence or by staining with ninhydrin or KMnO4 reagents.  
3.5.2 General Methods 
High performance liquid chromatograph (HPLC): Prodrug quantitation was performed 
on a Waters Breeze HPLC system (Waters, Milford, MA, USA) using a Kinetex 5 µ C18 
100A Phenomenex column. HPLC grade acetonitrile and methanol were purchased from 
Fisher Chemical. For all three ProTide samples, 10 mM potassium phosphate monobasic 
buffer solution (10 mM KH2PO4) was used at a flow rate of 1 mL/min. Specifically, AlaMe 
was eluted in 10 mM KH2PO4/acetonitrile (65/35, v/v) mobile phase with a retention time 
of 3.8 min; PheMe had a retention time of 4.2 min in 10 mM KH2PO4/acetonitrile (55/45, 
v/v), while PheC22 had a retention time of 7.0 min in 10 mM KH2PO4/methanol (2/98, v/v). 
Nuclear Magnetic Resonance (NMR): NMR spectra were recorded on a Bruker 
Avance-III HD (Billerica, MA) operating at 500 MHz, a magnetic field strength of 11.7T. 
Proton NMR data is reported in ppm downfield from TMS as an internal standard. 
Mass Spectrometry (MS): Mass spectra were obtained on a Waters Xevo TQ-S micro 
triple quadrupole mass spectrometer (Waters, Milford, MA, USA). 
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Fourier-transform infrared spectroscopy (FTIR): FTIR spectra were recorded on a 
Perkin-Elmer-spectrum attenuated total reflectance (ATR)-FTIR equipped with a UATR-
accessary (Perkin-Elmer, Inc., Waltham, MA, USA). 
3.5.3 Synthesis and characterization 
Z-Phe-Odoc (2): Triethylamine (1.35 g, 1.86 mL, 13.36 mmol, 2.0 equiv.), imidazole 
(454 mg, 6.68 mmol, 1.0 equiv.) and HATU (3.81 g, 10.02 mmol, 1.5 equiv.) were added 
to a solution of Z-Phe-OH (2 g, 6.68 mmol, 1.0 equiv.) and docosanol (2.4 g, 7.35 mmol, 
1.1 equiv.) in a mixture of CHCl3 (25 mL) and DMF (25 mL) at 0 ºC under an argon 
atmosphere. The mixture was then heated at 45 °C for 48 h and concentrated. The crude 
product was diluted with CH2Cl2 (100 mL), washed successively with 1 M HCl, saturated 
NaHCO3 and brine (80 mL each). The organic extract was dried over Na2SO4 and 
concentrated. The residue was purified by flash chromatography eluting with 4:1 
Hex/EtOAc to give Z-Phe-Odoc (3.46 g, 85 %) as a colorless solid. 1H NMR (500 MHz, 
CD3OD): 7.24-7.42 (m, 9H), 7.13 (d, J = 6.7 Hz, 2H), 5.25 (d, J = 4.0 Hz, 1H), 5.07-5.17 
(m, 1H), 4.68 (dd, J = 13.6, 6.0 Hz 1H), 4.12 (td, J = 13.6, 6.7 Hz 2H), 3.14 (m, 2H), 1.60 
(br, 2H), 1.29 (br, 38H), 0.92 (t, J = 6.9 Hz 3H). 13C NMR (125 MHz, CDCl3): δ 171.6, 
155.6, 136.2, 135.7, 129.2, 128.5, 128.4, 29.2, 28.4, 25.8, 22.7, 14.1. MS-ES+ (m/z): 
calcd. for C39H61NO4, 607.46 (100%), 608.46 (42.2%), 609.47 (8.7%); found, 608.46 
[M+H+]. 
H-Phe-Odoc (3c): To a solution of 2 (3.46 g, 5.695 mmol, 1.0 equiv.) in mixture of 
anhydrous MeOH (20 mL) and CHCl3 (10 mL) was added Pd/C (1.4g, 40% wt). The 
reaction mixture was cooled to 0°C followed by drop wise addition of triethylsilane39 (6.6 
g, 9.1 mL, 59.95 mmol, 10.0 equiv.). The reaction mixture was then stirred under an 
atmosphere of argon at room temperature for 16 h, filtered through Celite TM ® and then 
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concentrated to give H-Phe-Odoc (quantitative yield), that was precipitated from ether and 
used in the next step without further purification. 
General Procedure A: Aryl aminoacyl phosphorochloridates10 
The amino acid ester (1 mol equiv) and phenyl dichlorophosphate (1 mol equiv) were 
suspended in anhydrous CH2Cl2 (15 mL) and cooled to -78°C in a dry ice/ acetone bath. 
To this mixture, a pre-cooled (-78°C) solution of anhydrous trimethylamine (2 mol equiv) 
in CH2Cl2 was added drop-wise, and the resultant solution was stirred and gradually 
warmed to room temperature over 32 h under an inert argon atmosphere. The reaction 
mixture was concentrated on a rotary evaporator to yield a white solid that was suspended 
into diethyl ether and filtered. The filtrate was concentrated to give aryl aminoacyl 
phosphochloridates that were used in the next coupling step without further purification. 
General Procedure B: Abacavir ProTides10 
ABC (1 mol equiv) was dried by azeotroping from anhydrous pyridine, then suspended 
in anhydrous THF and cooled to -78 °C under an argon atmosphere. tert-BuMgCl (2 mol 
equiv, 1.0 M solution in THF) was added drop wise to the ABC suspension and the reaction 
mixture allowed to stir for an additional 10 min with cooling. A solution of aminoacyl 
phosphorochloridate (1.5 mol equiv) in THF was then added drop-wise and the resulting 
mixture was gradually warmed to room temperature and stirred for 48-90 h. The reaction 
mixture was then cooled to 0 °C, quenched with aqueous saturated ammonium chloride 
solution or methanol, concentrated, and the desired ABC ProTides isolated by flash 
column chromatography on silica gel eluting with 95%-90% CH2Cl2/CH3OH mobile phase. 
Preparation of AlaMe (5a). Synthesized according to general procedure B. On a scale 
of 1.0 g (3.49 mmol) of ABC, 1.4 g (2.66mmol, 76 % yield) of AlaMe product was formed: 
1H NMR (500 MHz, CD3OD): 7.66 (d, J = 6.6 Hz 1H), 7.10-7.40 (m, 6H), 6.15 (dd, J = 13.7, 
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5.7 Hz 1H), 5.97 (br, 1H), 5.53 (br, 1H), 4.08-4.30 (m, 2H), 3.85-4.0 (m, 1H), 3.23 (s, 3H), 
3.21 (br, 1H), 2.93 (br, 1H), 2.81 (td, J = 16.9, 8.3 Hz 1H), 1.65-1.80 (m, 1H), 1.20-1.40 
(m, 4H), 0.85 (app. d, J = 5.8 Hz 2H), 0.62 (br, 2H). 13C NMR (125 MHz, CDCl3): δ 175.4, 
161.7, 157.4, 152.2, 138.1, 137.2, 131.7, 130.6, 126.1, 123.7, 121.4, 114.8, 70.1, 60.5, 
52.7, 51.5, 47.1, 35.4, 24.3, 20.8, 20.5, 14.5, 7.6. 31P NMR (202 MHz, CD3OD); 3.87, 
3.58. MS-ES+ (m/z): calcd. for C24H30N7O5P, 527.20 (100%), 528.21 (26.0%), 529.21 
(2.7%); found, 528.2 [M+H+]. 
Preparation of PheMe (5b). Synthesized according to general procedure B. On a 
scale of 1.6 g (5.59 mmol) of ABC, 1.9 g (3.15mmol, 55 % yield) of PheMe was formed: 
1H NMR (500 MHz, CD3OD): 7.59 (d, J = 28 Hz 1H), 7.09-7.40 (m, 10H), 7.06 (d, J = 7.6 
Hz 1H), 6.01-6.08 (m, 1H), 5.87-5.95 (m, 1H), 5.43-5.53 (m, 1H), 4.15 (dd, J = 14.8, 9.1 
Hz 1H), 3.92-4.04 (m, 1H), 3.45-3.80 (m, 5H), 2.88-3.14 (m, 3H), 2.78-2.87 (m, 1H), 2.65-
2.74 (m, 1H), 1.50-1.58 (m, 1H), 0.82-0.89 (m, 2H), 0.57-0.65 (m, 2H). 13C NMR (125 
MHz, CDCl3): δ 174.5, 157.4, 152.2, 152.1, 151.6,138.3, 138.1, 137.2, 131.5, 130.7, 
130.6, 129.5, 127.9, 126.0, 125.9, 121.6, 121.1,114.8, 69.8, 69.7, 60.4, 57.9, 57.7, 52.6, 
46.8, 40.8, 35.4, 24.4, 7.6. 31P NMR (202 MHz, CD3OD); 3.62, 3.22. MS-ES+ (m/z): 
calcd. for C30H34N7O5P, 603.24 (100%), 604.24 (32.4%), 605.24 (2.4%); found, 604.24 
[M+H+]. 
Preparation of PheC22 (5c). Synthesized according to general procedure B. On a 
scale of 1.1 g (3.84 mmol) of ABC, 2.4 g (2.64mmol, 68% yield) of PheC22 product was 
formed: 1H NMR (500 MHz, CD3OD): 7.59 (d, J = 28 Hz 1H), 6.95-7.44 (m, 11 H), 6.04 (br, 
1H), 5.88-5.95 (m, 1H), 5.48 (br, 1H), 4.13 (d, J = 15.2, 8.7 Hz 1H), 3.89-4.09 (m, 3H), 
3.47-3.59 (m, 2H), 2.64-3.15 (m, 5H), 1.45-1.64 (m, 3H), 1.07-1.39 (br, 42H), 0.91 (t, J = 
6.6 Hz 3H), 0.84-0.87 (m, 2H), 0.61 (br, 2H). 13C NMR (125 MHz, CD3OD): δ 174.2, 157.4, 
154.3, 152.1, 144.9, 138.3, 138.2, 138.0, 137.9, 137.1, 131.5, 130.6, 130.5, 130.3, 
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130.1, 129.6, 128.9, 127.9, 126.7, 125.9, 124.1, 121.9, 121.4, 121.3, 121.1, 114.8, 69.9, 
66.7, 66.4, 63.2, 60.4, 58.1, 57.8, 46.8, 41.1, 35.4, 33.1, 31.2, 30.7, 30.5, 29.6, 29.5, 
26.9, 23.8, 14.5, 7.6; 31P NMR (202 MHz, CD3OD); 3.25, 3.54. MS-ES+ (m/z): calcd. for 
C51H76N7O5P, 897.56 (100%), 898.57 (55.2%), 899.57 (14.9%); found, 898.56 [M+H+]. 
3.5.4 Cell model for in vitro studies. 
Human peripheral blood monocytes were obtained and cultured as previously 
described40. Briefly, human peripheral blood monocytes were obtained by leukapheresis 
from HIV-1/2 and hepatitis B seronegative donors, followed by purification via 
countercurrent centrifugal elutriation. Elutriated monocytes were cultured as adherent 
cells in Dulbecco’s mimimum essential medium (DMEM) supplemented with 10% heat-
inactivated pooled human serum, 10 μg/mL ciprofloxacin, 50 μg/mL gentamicin, and 1000 
U/mL recombinant macrophage colony stimulating factor. Cells were maintained at 37 °C 
in a 5% CO2 incubator. Seven days later, differentiated macrophages (MDM) were used 
for the experiments. 
3.5.5 Antiretroviral activity of ABC and its ProTides. 
The antiviral activities of native ABC and ABC ProTides against HIV-1ADA were 
determined in MDM as previously described5. MDM were incubated with various 
concentrations of ABC or ABC ProTides for 60 min followed by infection with HIV-1ADA at 
a multiplicity of infection (MOI) of 0.01 for 4 h. The MDM were washed extensively with 
phosphate buffered saline (PBS) to remove excess virus particles. The cells were 
incubated an additional 10 days in the presence of the same concentration of drug used 
before infection. Cell culture medium was changed every other day with replacement of 
equivalent drug containing media. At day 10 post infection, supernatants were collected 
and analyzed for HIV-1 reverse transcriptase (RT) activity 41. 
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3.5.6 Intracellular level of CBV-TP of ABC and its ProTides. 
Intracellular levels of CBV-TP were measured as previously described9. MDM were 
treated with 10 µM ABC and ABC ProTides. At 3, 6, 12, 24 and 48 h after treatment, MDM 
were washed with PBS to remove excess free drug. The cells were then collected in 70% 
methanol. CBV-TP from MDM was extracted and quantitated by LC-MS/MS as previously 
described21. Sep-Pak QMA cartridges (360 mg, 37-55 µm; Waters) were used to separate 
CBV-TP from their mono- and di-phosphates counterparts.  The QMA cartridges were 
conditioned with 10 ml of 500 mM KCl followed by 10 ml of 5mM KCl.  Samples were 
loaded onto the cartridges and washed with 15 ml of 75mM KCl.  The triphosphate fraction 
was eluted with 3 ml of 500 mM KCl and collected for de-phosphorylation.  The pH of the 
TP fraction was lowered to 4.25 by adding 15 µl ammonium acetate buffer (pH 4,10 mM) 
per ml eluate, and dephosphorylated by adding one unit of type XA sweet potato acid 
phosphatase per ml eluate and incubating at 37 °C for 30 min.  The 15N213C-3TC and d4-
ABC internal standard was added at this point.  Samples were then loaded onto Waters 
OASIS HLB cartridges (60 mg, 30 µm; Waters) pre-conditioned with 3 ml MeOH and 3 ml 
H2O and washed with 3.5 ml H2O to remove salts.  The nucleosides of interest were then 
eluted with 1.5 ml of MeOH and evaporated under vacuum.  Once dry, the residue was 
reconstituted with a 100 µl of 25% MeOH and stored in the -20 °C freezer until the time of 
LC–MS/MS analyses. The LC-MS/MS system comprised of a Waters ACQUITY ultra-
performance liquid chromatography (UPLC) system (Waters, Milford, MA) coupled to a 
triple quadrupole mass spectrometer with electrospray ionization (ESI) source (Waters 
Xevo TQ-XS).  For the indirect quantification of TPs, chromatographic separation was 
performed with an ACQUITY UPLC using CSH analytical column (2.1×100 mm, 1.7µm; 
Waters) equipped with a guard column (Waters, Milford, MA).  Mobile phase A consisted 
of ammonium bicarbonate (pH 7, 7.5 mM) and mobile phase B was methanol. The flow 
 64 
rate was 0.25 ml/min. The initial mobile phase composition was 12 % B for the first 2.5 
min, gradually increased to 30 % B over 4 min, gradually increased again to 95 % B over 
3.5 min, and then held constant for one min. Mobile phase B was then reset to 12 % over 
0.25 min and the column was equilibrated for 2.75 min before the next injection. The total 
run time was 13 min. The mass spectrometer was operated in the positive ion mode using 
multiple reaction monitoring (MRM). The following transitions were monitored: m/z 
230→112 for 3TC, m/z 248→152 for CBV, m/z 287→191 for ABC, m/z 233→115 for the 
internal standard (IS) 15N213C-3TC, and m/z 291→195 for IS d4-ABC. 3TC, CBV, ABC, 
15N213C-3TC, and d4-ABC were detected at a cone voltage of 22, 2, 4, 12, and 2 V, 
respectively, and a collision energy of 12, 12, 20, 10, and 20 V, respectively.  
3.5.7 Cell viability of ABC and its ProTides. 
A CCK-8 Kit was purchased from Dojindo and used to test cell viability after treatment 
with ABC and its ProTides. Briefly, MDM plated in a 96-well plate were treated with 100 μl 
of 0-400 µM ABC and its ProTides for 24 h. Drug containing medium was removed and 
replaced with fresh medium. Ten μl of CCK-8 solution was added to each well followed by 
incubation of the plate for 2 h at 37˚C. The absorbance (at 450 nm) of each well was 
measured using a microplate reader. The cell viability was calculated according to 
manufacturer’s instructions. 
3.5.8 Stability Assay in Serum.  
The experiment was carried out by adding each ProTide into 100 μl human serum to 
reach a final concentration of 15ug/ml in glass vial, and duplicate samples were used for 
each ProTide. After incubating the samples at 37 °C with shaking for 24 h, 900 μl of MeOH 
was added to stop the reaction.  Samples were vortexed for 3min, then centrifuged down 
at 16,000 g for 10 min. The supernatants were transfer to new 2 ml tubes and evaporated 
to dryness under vacuum. The samples were reconstituted using 50 μl of MeOH, vortexed 
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for 3 min and centrifuged down at 16,000 g for 10 min. The supernatants were analyzed 
by HPLC for drug concentrations. For control sample (0 min), MeOH were added first to 
stop the enzyme before adding the ProTides.  
3.5.9 Preparation and characterization of ABC ProTide nanoformulations. 
Lipid-PLGA hybrid nanoparticles loaded with AlaMe (NAlaMe) were prepared using a 
modified single emulsion solvent evaporation technique as described previously 23. Briefly, 
a mixture of lipids consisting of DSPC, DSPE-PEG2k and DSPG in 10:5:1 weight ratio was 
coated over drug loaded PLGA nanoparticles to enable sustained release of the loaded 
cargo. A 2:1:1 weight ratio of PLGA core to drug to lipid shell was used. NPheMe and 
NPheC22 were prepared by high-pressure homogenization (Avestin EmulsiFlex-C3; 
Avestin Inc., Ottawa, ON, Canada) as previously reported6. Briefly, PheMe or PheC22 (1% 
w/v) and poloxamer 407 (P407, 0.2% w/v) were premixed at room temperature overnight 
followed by homogenization at 20,000 psi until the desired particle size and polydispersity 
index (PdI) were achieved. Effective diameter (Deff), PdI, and ζ-potential were measured 
by dynamic light scattering (DLS) (Malvern Zetasizer Nano Series Nano-ZS, Malvern 
Instruments, Westborough, MA, USA).  
3.5.10 Cell uptake and retention of ABC phosphoramidate prodrug 
nanoformulations. 
Uptake and retention of nanoformulations were determined in MDM as previously 
reported3-6,22. Briefly, MDM were treated with different nanoformulations at a concentration 
of 100 µM for 1, 2, 4 and 8 h. At select time points, adherent MDM were collected in 1 mL 
PBS after washing with 1 mL PBS twice.  MDM were pelleted by centrifugation at 3,000 
rpm for 8 min. The cell pellet was reconstituted in 200 µl methanol and probe sonication 
(10 sec) was used to break the cells and extract drugs. After probe sonication, cell debris 
was pelleted by centrifugation at 14,000 rpm for 10 min and 4˚C. The supernatant was 
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analyzed for prodrug level using HPLC-UV/Vis. For retention, MDM were treated with 100 
µM different nanoformulations for 8 h. The nanoformulation-containing media were 
replaced with fresh media after washing MDM with PBS twice. At days 1, 5, 10, 15, 20, 25 
and 30, MDM were collected in 1mL PBS after washing with 1 mL PBS twice.  The samples 
were processed as described above for analysis using HPLC.  
Intracellular CBV-TP levels were also measured for as an indicator of cell uptake and 
retention. Briefly, cells were scraped into PBS, pelleted by centrifugation at 3,000 rpm for 
8 min, and reconstituted in 200 µl 70% methanol. CBV-TP was extracted, and the samples 
were analyzed by LC-MS/MS as previously reported21. 
3.5.11 Antiretroviral efficacy of nanoformulations. 
Antiviral efficacies of ABC and the ProTide nanoformulations in MDM were assessed 
as previously described5. MDM were treated with 100 µM different nanoformulations for 8 
h. Then nanoformulation-containing medium was replaced with fresh medium after 
washing MDM with PBS twice. Half media changes were conducted every other day. At 
predetermined time points, days 1, 5 ,10, 15, 20, 25 and 30, MDM were infected with HIV-
1ADA for 4 h at a MOI of 0.1 and cultured with every-other-day half media changes for an 
additional 10 days. At day 10, supernatant was collected for RT assay and MDM were 
fixed with paraformaldehyde and immunostained for expression of HIVp24. Untreated, 
uninfected MDM served as negative controls (control), while MDM exposed to HIV-1ADA 
but not treated with nanoformulations, served as positive controls (HIV-1).  
For NPheC22, a concentration response study was also conducted. MDM were 
treated with 1, 10, 25, 50 or 100 µM NPheC22 for 8 h. The treated MDM were then washed 
twice with PBS. MDM were cultured for an additional 30 days in fresh media with half 
media changes every other day. At day 30, MDM were challenged with HIV-1ADA at a MOI 
of 0.1 for 4 h. Excess virus was washed out with PBS and MDM were cultured for another 
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10 days. At day 10 post-exposure, media were collected for RT assay and MDM were 
fixed and immunostained for expression of HIVp24 antigen. 
3.5.12 In vivo study with rats. 
Animal PK studies were conducted in accordance with the University of Nebraska 
Medical Center Institutional Animal Care and Use Committee. Male Sprague Dawley rat 
(250g; Jackson Labs, Bar Harbor, ME) were injected with NPheC22 (45 mg/kg ABC-eq.) 
intramuscularly (IM; caudal thigh muscle). Whole blood samples were collected at 2, 24 
and 168 hours after injection. PBMC were separated from whole blood samples using 
HISTOPAQUE 1083 (Sigma# 1083-1) following manufacturer’s instruction. CBV-TP were 




Figure 3.1 Synthesis Scheme of ABC ProTides. 
Reagent and condition: Step 1(a) 1-docosanol, HATU, imidazole, Et3N, DMF/CHCl3, 
45 ℃, 48 h; Step 1(b) Pd/C, Et3SiH, MeOH/CHCl3 (1:1 v/v), rt, 16 h. Step 2(a) Phenyl 
dichlorophosphate, Et3N, CH2Cl2, -78 ℃-rt, 16 h. Step 3(a) ABC, tert-BuMgCl, THF, -78 ℃- 
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Figure 3.5 FTIR pectra of ABC, AlaMe, PheMe and PheC22 
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Figure 3.6 The structure and biological characterization of ABC and its ProTides. 
 A. AlaMe, PheMe and PheC22 were synthesized based on ProTide technology. B. 
EC50 of ABC, AlaMe, PheMe and PheC22 against HIV-1ADA were determined in MDM. C. 
Intracellular CBV-TP levels were measured after MDM were treated with 10 μM free ABC, 
AlaMe, PheMe and PheC22 for various times. D. Cytotoxicity of ABC, AlaMe, PheMe and 
PheC22 in MDM. Results are shown as percentage of cell viability as compared to 




Figure 3.7 Preparation and characterization of nanoformulations. 
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A. NAlaMe was prepared by a modified single emulsion solvent evaporation technique. 
B. NPheMe and NPheC22 were produced by high pressure homogeinization. C. TEM 




Table 3.1 Characterization of Nanoformulationsa 
Name Deff (nm) PdI ζ- potential (mV) 
Drug loading 
(%) 
NAlaMe 237 ± 2 0.15 ± 0.03 - 43.4 ± 0.7 3.4 ± 0.2 
NPheMe 339 ± 17 0.35 ± 0.01 - 14.3 ± 0.3 43.4 ± 0.5 
NPheC22 329 ± 3 0.28 ± 0.01 - 45.0 ± 0.4 47.4 ± 2.0 
Effective diameter (Deff), polydispersity index (PdI) and ζ- potential of nanoformulation 
samples diluted in water were determined by dynamic light scattering (DLS). Drug 
loadings of lyophilized nanoformulations were determined by HPLC. Drug loading (%) = 




Figure 3.8 Uptake and retention of nanoformulations in MDM. 
 A and B. For cell uptake, MDM were treated with 100 μM ABC or prodrug 
nanoformulations for 8 hr. C and D. Drug retention in MDM was determined after an 8 h 
drug loading followed by half media exchanges every other day for up to 30 days. 
Intracellular drug concentrations and CBV-TP levels were determined. Data are expressed 
as mean ± SD for n = 3 samples per group. E. TEM was performed to visualize 
morphologies of formulation-loaded MDM after 8 h incubation with nanoformulations. 
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Figure 3.9 ABC ProTide nanoformulations protect MDM from HIV-1 infection 
over time. 
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MDM were treated with free ABC or nanoformulations of ABC ProTides containing 100 
μM ABC equivalent for 8 h. At predetermined time points, MDM were challenged with HIV-
1ADA. Samples were collected for antiretroviral activity assessment ten days after viral 
challenge by (A) measuring HIV RT activities and (C) staining HIV-1p24 antigen. (B) and 
(D) MDM were treated with 1, 10, 25, 50 and 100 μM NPheC22 for 8 h. At day 30 post 
treatment, MDM were challenged with HIV-1ADA. Ten days after infection, culture media 
were collected for RT assay and cells were fixed and stained for HIV-1p24 antigen. Data 




Table 3.2 CBV-TP level in PBMC for pilot in vivo study 
Time (Hours) 
CBV-TP level (fmol/million cells) 
Rat 1 Rat 2 
2 1.07 7.84 
24 4.23 5.36 
168 4.51 9.37 
Rats were injected Intramuscularly with 45mg/kg ABC equivalents using NPheC22. PBMC 
were extracted from whole blood samples collected 2, 24 and 168 hours after injection. 
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Chapter 4  




Nucleoside analogs transcriptase inhibitor (NRTIs) served as the “backbone” of 
antiretroviral drug regimen. But, the properties of NRTIs limit their possibilities for the 
redevelopment as long-acting injectable products using conventional pharmaceutical 
manufacturing approaches. In the first phase of application of LASER ART, we reduced 
the solubility of ABC by conjugating it with myristoyl chloride (MABC) and successfully 
nanoformulated MABC by high pressure homogenization. Detectable level of ABC was 
observed during the whole 14-day time period in vivo study, Then, we have tried to develop 
second generation long-acting (LA) ABC nanoformulation by adding ProTides technology 
to our LASER ART platform. The developed ABC ProTide LA showed significant 
improvements in terms of both potency and extended release. In this chapter, we 
synthesized a variety of ABC ProTides LA with different combination of amino acid side 
chains and fatty alcohols and their in vitro/ in vivo behaviors were thoroughly examined. 
4.2 Introduction 
Exciting breakthroughs have been continuously reported in HIV/AIDS research. 
However, before the appearance of a safe, affordable and repeatable cure, the powerful 
combined antiretroviral drug “cocktail” remains as the gold standard for HIV/AIDS 
treatment. And patients can expect a normal life as compared to uninfected people. 
Moreover, a lot of “cure” strategies proposed still rely on antiretroviral drugs to suppress 
the viral replication and reduce the viral reservoirs. In recent years, long-acting (LA) 
formulations for the delivery of antiretroviral drugs and treatment of HIV/AIDS have 
received much attention since LA agents have the potential advantages of requiring less-
than-daily dosing intervals, improving pharmacokinetic profile of antiretroviral drugs and 
reducing the risk of viral mutation and drug resistance caused by missed doses. Two LA 
injectable agents, cabotegravir (GSK1265744 LA, CAB LA, integrase inhibitor) and 
 88 
rilpivirine (TMC278 LA, RPV LA, Non-nucleoside reverse transcriptase inhibitor), are in 
advanced stages of clinical trials now. 
On the other hand, nucleoside analogs transcriptase inhibitor (NRTIs) served as the 
“backbone” of antiretroviral drug regimen. Generally, two NRTIs are used along with a 
drug from other classes. But, the dosing frequency of LA reagent is determined by the 
drug’s aqueous solubility/hydrophobicity, antiretroviral potency/daily dose and system 
clearance/half-life1 which means all the approved NRTIs are not suited for redevelopment 
as long-acting injectable products using conventional pharmaceutical manufacturing 
approaches. For example, the solubility, EC50/daily dose and half-life of abacavir (ABC) 
are 2 mg/ml, 0.07 to 5.8 μM/600 mg (8.6 mg/kg), 1.54 h (20 h for CBV-TP), while they 
were 0.1 mg/ml, 0.22 to 1.3 nM/0.30 mg (0.4 mg/kg), 40 h for CAB. However, in order to 
achieve equivalent therapeutic drug exposure for LA formulation when compared with 
daily, oral version of NRTIs, the solubility and antiviral potency of NRTIs definitely need to 
be adjusted in scale of one or two orders of magnitude and that is the strength of our 
LASER ART platform. We have reduced the solubility of ABC by conjugating it with 
myristoyl chloride (MABC) and successfully nanoformulated MABC by high pressure 
homogenization2. Detectable level of ABC was observed during the whole 14-day time 
period in vivo study, while the CBV-TP level was not ideal3. Clearly, the antiretroviral 
activity of ABC also needs to be adjusted. In the last two chapters, we have proved that 
ProTide technology can be used for this purpose. The developed ABC ProTide LA showed 
significant improvements in terms of both potency and extended release6. In this paper, 
we dived further in to this strategy, a variety of ABC ProTides LA with different combination 
of amino acid side chains and fatty alcohols have been synthesized and their in vitro/ in 
vivo behaviors were thoroughly examined. 
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4.3 Results 
4.3.1 Synthesis of ABC ProTides LA 
Six ABC ProTides were synthesized with high yields (Figure 4.1). The chemical 
structure of ABC ProTides was characterized by 1H NMR, 13C-NMR, 31P NMR and FT-IR 
spectra and compared to ABC as shown in Figurs 4.2-4.5. A broad singlet at 1.26 ppm 
correspond to the repeating methylene protons of the fatty acid alkyl chain ABC ProTides. 
Multiplet at 7.96 - 9.16 ppm correspond to the benzene ring protons. Splitting of peaks in 
the 31P-NMR spectra of ProTides was associated with co-existence of two stereoisomers 
at the phosphorus atom16. In addition, absorption bands at 2855 and 2923 cm−1 in the FT-
IR spectrum associate with the C-H stretches of the fatty acid ester chain. A band at 
1760 cm−1 is attributed to the carbonyl C=O stretch of the ester bond present in the fatty 
esters.  
4.3.2 Antiretroviral activity and Cytotoxicity of ABC ProTides LA 
At least 5-fold improvements of EC50 were observed with ABC ProTides against HIV-
1ADA in MDM (Table 4.1). The EC50 of ABC was 21.4 nM while the EC50 for AlaC14, AlaC18, 
AlaC22, PheC14, PheC18 and PheC22 were 1.1, 2.2, 3.7, 0.18, 1.3 and 3.4 nM, 
respectively. These improvements have not been seen with myristoylated abacavir 
(MABC)2 and supported the rationale design of second-generation ABC LA. Similarly, 
improvements of antiretroviral efficacy were also observed for ABC ProTides against HIV-
1NLF-3 in CEM CD4+ T cells but to a less extent. The EC50 of ABC was 2.66 μM. However, 
for ABC ProTides, they were 0.24, 0.30, 2.20 and 1.21 μM for AlaC14, AlaC18, AlaC22 
and PheC14, respectively. PheC18 and PheC22 were less potent as compared to ABC, 
and the EC50 of PheC18 and PheC22 were 25.64 and 43.03 μM, respectively. In general, 
the EC50 of ABC ProTides increased with longer fatty acid esters. L-phenylalanine based 
ABC ProTides were more potent than L-alanine based ABC ProTides in MDM but not in 
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CEM CD4+ T cells. This was probably because MDM unlike T cells contained numerous 
enzymes that might even include chymotrypsin-like esterase and Cathepsin G, which are 
responsible for the metabolized of ABC ProTides especially L-phenylalanine based ones7.  
The Cytotoxicity of ABC ProTides were also measured. Since the highest drug 
concertation tested is 400 μM, the CC50 level could not be accurately calculated. However, 
while ProTides did show increases in cytotoxicity, the selectively index (SI) was still more 
favorable compared to ABC especially for alanine-based ProTides, similar to previous 
report8. 
4.3.3 Intracellular CBV-TP level 
It was reported9 that the improved antiretroviral activity of ABC ProTide was due to 
markedly increase of its metabolite (CBV-TP) inside the cells. As Figure 4.6A shows, in 
MDM, during the 48-h incubation time period, the CBV-TP level of ABC ProTide treatment 
groups were at least 2-fold higher than ABC. Specifically, 6 h after incubation, the CBV-
TP level for ABC was 61.8 fmol/10^6 cells, and 2820.6, 2339.7, 1523.6, 378.7, 356.4 and 
157.8 fmol/10^6 cells for AlaC14, AlaC18, AlaC22, PheC14, PheC18 and PheC22, 
respectively. 48 hr after incubation, the CBV-TP level for ABC was 40.84 fmol/10^6 cells, 
and 264.9, 207.5, 890,9, 282.5, 392.8, 692.0 fmol/10^6 cells for AlaC14, AlaC18, AlaC22, 
PheC14, PheC18 and PheC22, respectively. For Ala-based ProTides, CBV-TP levels 
reached higher Cmax soon after incubation then the levels decreased faster.  For Phe-
based ProTides, the CBV-TP levels were more stable and showed very slow decrease 
rate. In general, Ala-based ProTides had higher Cmax but Phe-based ProTides had higher 
C48hr. 
CBV-TP levels were also recorded in CEM CD4+ T cells (Figure 4.6B) after incubated 
with free ABC ProTides. In general, the CBV-TP levels were higher or similar in T cells as 
compared to in MDM, especially for ABC, although ABC and ABC ProTides was 
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significantly more potent in MDM than in T cells. This observation had been reported 
before and was explained by the fact that dNTP pool levels is markedly lower in MDM than 
in T cells, thus CBV-TP can better compete with dNTP as the substrate for HIV reverse 
transcriptase9. Another difference was that CBV-TP levels kept rising during the 48 hr 
incubation time period for ABC and all ABC ProTides treatment in T cells. 7,5- and 4.9- 
fold higher CBV-TP levels were recorded for AlaC14 (2082.7 fmol/10^6 cells) and AlaC18 
(1346 fmol/10^6 cells) as compared to ABC (276.73 fmol/10^6 cells) at 48 hr. Other ABC 
ProTides showed less CBV-TP level as compare to ABC, but the trends correlated with 
EC50 results. Again, there were significantly negative correlation between chain length of 
fatty esters and drug potency against HIV-1 (CBV-TP level). 
4.3.4 Metabolic stability assay in serums 
The stability of ABC ProTides in circulation is very impotent, premature degradation of 
ProTides will diminish their cell membrane penetration ability and reduce their potency. 
As Figure 4.7 shows, all ABC ProTides except AlaC14 were stable after 24 h incubation 
with human serum, while AlaC14 and PheC14 suffered seriously degradation when 
incubating with the rat serum. The level of AlaC18 was also slightly decreased in rat serum. 
This difference is possibly attributed to the species difference of esterase expression and 
hydrolase activity. It was reported circulated carboxylesterase (CES) was only abundant 
in rabbits, mice and rats, but not in primates10. And CES1 is proposed to be responsible 
for the intracellular activation of TAF in human for the treatment of HBV. These results 
suggested that interpretation of pharmacokinetic data conducted in rodent model need to 
consider the possibility of premature degradation of ProTides in the circulation.  
4.3.5 Preparation and characterization of ABC ProTide LA nanosuspensions 
ABC ProTides nanosuspensions were prepared successfully by high-pressure 
homogenization with high drug loading (Figure 4.8, Table 4.2). Intensity-mean Z-
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averaged particle diameter (Deff), ζ-potential, and polydispersity index (PdI) of 
nanosuspensions determined by DLS were also summarized in Table 4.2. All ABC Protide 
nanosuspensions had sizes around 250 - 300 nm with PdI<0.3 and negative surface 
charges. As observed by TEM, all nanosuspensions had spherical shape. When store at 
4 ℃, the size of NAlaC14 increased 24% after seven days, while NAlaC18 and NAlaC22 
were stable for at least one month. Similar trends were observed for phenylalanine-based 
ABC ProTides (data not shown). It was suggested LogP of a drug positive correlated with 
the particle stability11. The cLogP calculated by ChemDraw was 5.2, 7.3 and 9.4 for 
AlaC14, AlaC18 and AlaC22, respectively. 
4.3.6 Uptake, retention and release studies in MDM. 
Cell viability assay revealed that all ABC ProTides LA nanosuspensions with drug 
concentration up to 400 µM had no or little cytotoxic effect on MDM after 8 h incubation.50 
µM ABC or ABC ProTide nanosuspensions was selected for MDM based in vitro study. 
As Figure 4.9A-B shows, in MDM uptake study, NPheC18 and NPheC22 had the highest 
prodrug levels, followed by NAlaC22, NAlaC18, NPheC14 and NAlaC14. However, in 
terms of CBV-TP levels during the uptake study, NAlaC14 treatment group had the highest 
CBV-TP level (19673.2 fmol/10^6 cells), followed by NAlaC18 (7966.0 fmol/10^6 cells), 
NAlaC22 (3798.1 fmol/10^6 cells), NPheC14 (2449.1 fmol/10^6 cells), NPheC18 (994.4 
fmol/10^6 cells) and NPheC22(1492.0 fmol/10^6 cells) at 8 h while the CBV-TP level for 
ABC was 698.0 fmol/10^6 cells. Obviously, the hydrophobicity and lipophilicity of each 
ProTide affected or determined the results of this uptake study. For AlaC18, PheC22, and 
AlaC22 with higher hydrophobicity and lipophilicity, their nanoparticles were comparable 
stable inside the cell and showed higher prodrug levels. While NAlaC14, once inside the 
cells, was immediately digested, and AlaC14 was released and metabolized to its 
metabolites.  
 93 
The hydrophobicity and lipophilicity of each ABC ProTide also had influence on their 
retention results (Figure 4.9C-D). For Ala-based ProTides, the prodrug levels of NAlaC14 
or NAlaC18 treatment group was under detection limit at day 1 or day 14, respectively, 
while the prodrug level for NAlaC22 (1.5 nmol/10^6 cells) was still above detection level 
until day 28. For Phe-based ProTides, similar results were observed, but since Phe-based 
ProTides were more hydrophobic then their Ala-based counterparts, prodrug level for 
NPheC14 was detectable up to day 14, while NPheC18 and NPheC22 treatment group 
showed high amounts of prodrugs were still retained inside the MDM at day 28. The 
prodrug level of NPheC22 treatment group was decreased in a strikingly slow rate. CBV-
TP levels in MDM for retention study were correlated with the prodrug levels. They are 
696.0, 1145.7, 1382.7, 317.0, 1332.1 and 1256.7 fmol/10^6 at day 1, respectively, then 
the levels slowly decreased to 29.0, 110.8, 435.0, 132.02, 447.0 and 294.3 fmol/10^6 cells 
for NAlaC14, NAlaC18, NAlaC22, NPheC14, NPheC18 and NPheC22, at day 28, 
respectively. CBV-TP level for ABC treatment group was 10.7 fmol/10^6 cells then fell 
below detection level at day 3. 
We have collected media from long-acting dolutegravir (NMDTG) treated MDM, and 
treated CD4+ T cells with such media. Results showed that this drug-containing media 
released by MDM was able to protect CD4+ T cells against HIV infection up to day 2412. 
Since it is as important for MDM to release enough drugs to other cells as retain enough 
drugs for other cells include T cells and MDM itself against HIV infection, whole media 
changes were always conducted one day before the cell collection time of retention study, 
then the media were collected and analyzed to study the release profile of each treatment 
group (Figure 4.9E). No prodrug had been detected for NAlaC14 treatment group at day 
1, which, again, suggested that all AlaC14 delivered into the cells had been metabolized. 
For NAlaC18, NAlaC22, NPheC14, NPheC18 and NPheC22, the prodrug levels were 11.7, 
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8.7, 17.2, 7.1 and 1.6 nmol/10^6 cells, respectively. Higher release rate was observed for 
Ala-based ProTides as compared to its Phe-based counter parts in an order C14> C18> 
C22. Moreover, particles had size range between 50-150 nm has been detected in the 
media and was stained positive for one of the exsosome marker ALIX (data no shown). 
ExoquickTM was used to extract such particles, both CBV-TP and prodrugs can be 
detected inside those particles (no prodrug can be detected for NAlaC14 treatment group). 
When incubated these particles with CD4+ T cells, uptake of these particles can also be 
measured. These particles released by MDM might serve as a carrier to disseminate CBV-
TP and prodrugs, it might also help targeting T cells or other reservoirs13, which are worth 
further investigation.  
4.3.7 In vitro antiretroviral study in MDM. 
To determine whether sustained intracellular prodrug and CBV-TP level from ProTide 
formulations would translate into improved antiretroviral activity, MDM were challenged 
with HIV-1ADA for up to 28 days after a single 8 h treatment with 50 µM ABC equivalent 
dose of different nanosuspensions. HIV-1 reverse transcriptase (RT) activity and p24 
antigen expression were assessed in infectious supernatants and adherent MDM on day 
10 post-infection. As shown in Figure 4.10, complete total viral inhibition was observed 
for up to 28 days for NAlaC18, NAlaC22, NPheC14, NPheC18 and NPheC22 measured 
by RT assay. At day 28, 8.5 % RT activity was recorded for NAlaC14. HIV-1p24 antigen 
staining confirmed these results. In contrast, minimal protection against viral infection was 
observed with native ABC at all time points. These results paralleled prolonged high 
intracellular CBV-TP levels for all the ABC ProTides nanosuspension treatment group.  
4.3.8  In vivo pharmacokinetic study.  
To investigate the in vivo behavior of nanoformulated ABC ProTides, male Sprague 
Dawley rat were injected intramuscularly with ABC, NAlaC14, NAlaC18, NAlaC22 and 
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NPheC18 (70 mg/kg ABC-eq. and 10mg/kg human dose-eq.). For ABC, the CBV-TP level 
was decreased from 488.22 to 25.42 fmol/10^6 cells within one day and was below 
detection level at day 7 (Figure 4.11B). For NAlaC14, unlike ABC, the CBV-TP level 
(44.17 fmol/10^6 cells) peaked at day 1 and was 3.3 fmol/10^6 cells at day 7 with a range 
of 1.73 to 6.19 fmol/10^6 cells. NAlaC18 also had Cmax (18.4 fmol/10^6 cells) at day 1, and 
the CBV-TP level only decreased by 2-fold at day 7 (9.74 fmol/10^6 cells), the level was 
still about detection level at day 14 (0.42 fmol/10^6 cells). For NAlaC22 and NPheC18, we 
observed constant level of CBV-TP level (around 1-2 fmol/10^6 cells) up to day 7 or day 
14. Quantifiable amounts of CBV-TP level can be detected for NPheC18 until day 28 (0.5 
fmol/10^6 cells). It is worth to mention, we detected 2% AlaC18 in NAlaC14 later which 
might affect the results to some degree. 
4.4 Discussion 
In the development of LA nanoformulation, the perfect candidates should be able to 
maintain sustained but effective level of drugs over a period of time. Specifically, MDM 
was reported, first, one of the target cells and reservoir for HIV infection and replication. 
And it also served as a carrier for the delivery of drugs to other cells and tissues17. 
Moreover, MDM actively affect the pharmacokinetics profile of LA nanoformulation, it can 
serve as secondary depots and modify the dissolution and release of drugs from 
formulations14-16.  
By employing the ProTide technology, we were able to improve the potency of drugs 
up to 100-fold or 10-fold in MDM or CEM CD4+T cells against HIV infection. The active 
metabolite CBV-TP was also increased by up to 45-fold of 8-fold in MDM or CEM CD4+T 
cells. By applying our lab’s expertise on top of that, potent and long-acting ABC ProTides 
nanoformulations were developed. In our study, we observed improved uptake, retention 
and release profiles of ABC ProTides nanoformulation in MDM as compare to ABC. 
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Significant sustained and high amounts of CBV-TP were observed in all ABC ProTides 
nanoformulations treated MDM and protected MDM against HIV infection up to day 30. It 
is possible CBV-TP and prodrugs can both released by treated MDM. ProTides modified 
with myristyl alcohol (C14) has the highest release rate, followed by stearyl modified 
alcohol (C18) from nanoformulations treated MDM. Docosyl modified ProTides (C22), 
especially PheC22, was released from MDM at a small but very constant amounts. 
This in vitro observation almost paralleled exactly to what we observed in in vivo study. 
In general, as compare to ABC, sustained release was observed with all tested ABC 
ProTides nanoformulations. Among them, NAlac14 had highest Cmax, but CBV-TP level 
decreased 13-fold during the first week, while only 2-fold difference of CBV-TP level was 
observed for NAlaC18. Constant CBV-TP levels were observed for NAlaC22 and 
NPheC18. In this study, we were able to achieve clinically relevant CBV-TP level, reported 
by GSK in study CNA 10905, with NAlaC18 for seven days with single injection at 10mg/kg 
human dose equivalent. While it is worth to mention that species differences might affect 
the pharmacokinetics outcomes. We did observe our ABC ProTides are less stable in 
human serum which might diminished their penetration into cells. Moreover, metabolism 
and clearance rate are slower in human as compared to rat which might leads to higher 
CBV-TP level that will last longer. Such phenomenon has been reported for RPV LA, which 
has been tested in both rat and human18. Further investigation is needed for our long-
acting ABC ProTide nanoformulations. 
In conclusion, we have successfully proved in this chapter that our strategy, combining 
ProTides technologies with LASER ART developed in our lab, can improved both antiviral 
potency and release profiles of NRTIs using ABC as example. This may pave the way 
towards the development of an actual LA injectables of NRTIs for clinics, which can not 




All chemical synthesis reactions were performed under a dry argon atmosphere unless 
otherwise noted. Reagents were obtained from commercial sources and used directly; 
exceptions are noted. Abacavir was purchased from BOC Sciences Inc. (Shirley, NY). 
phenyl dichlorophosphate, N-(carbobenzyloxy)-L-phenylalanine, N-(carbobenzyloxy)-L-
alanine, tetradecanol, octadecanol, docosanol, dichloromethane (CH2Cl2), chloroform 
(CHCl3), N,N-dimethylformamide (DMF), triethylamine (Et3N), diethyl ether, 
tetrahydrofuran (THF), tert-Butylmagnesium chloride solution (tert-BuMgCl, 1.0M in THF), 
triethylsilane (Et
3
SiH), methanol and poly (D, L-lactide-co-glycolide; lactide:glycolide 
(75:25), mol wt 66,000-107,000) (PLGA) were purchased from Sigma-Aldrich (St. Louis, 
MO). Distearoyl-phosphatidylethanolamine-methyl-polyethylene glycol conjugate-2000 
(DSPE-mPEG2k) was purchased from Corden Pharma (Cambridge, MA). 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b] pyridinium 3-oxid 
hexafluorophosphate (HATU) was obtained from Bachem Inc. (Torrance, CA) while 
palladium, 10% on activated carbon, was purchased from STREM Inc. (Newburyport, MA). 
Flash chromatography was performed using flash silica gel (32-63 μ) from SiliCycle Inc. 
(Quebec, Canada). Chemical reactions were analyzed by thin layer chromatography 
(T.L.C) on precoated silica plates (200 μm, F-254) from Sorbtech technologies Inc. 
(Norcross, GA). The compounds were visualized by UV fluorescence or by staining with 
ninhydrin or KMnO4 reagents. CD68 Polyclonal Antibody (Catalog # PA5-78996) was 
purchased from Thermo Fisher Scientific. 
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4.5.2 Synthesis of ABC ProTides LA 
ABC ProTides were synthesized as previously reported6,8. Briefly (Scheme 1), alanine 
or phenylalanine esters were prepared with HATU/TEA/imidazole through esterification of 
Cbz-protected amino acid and long-chain fatty alcohols followed by removal of Cbz. Then, 
the aryl amino acid ester phosphorochloridates were synthesized from amino acid esters 
with commercially available phenyl phosphorodichloridate in the presence of TEA. Each 
of the amino acid ester phosphorochloridates was then reacted with ABC in the presence 
of tert-BuMgCl and purified by flash column chromatography with DCM/MeOH. Successful 
synthesis of ABC ProTides was confirmed by 1H, 13C and 31P NMR spectra.  
AlaC14: 1H NMR (500 MHz, CD3OD): 7.64 (d, J = 5.9 Hz, 1H), 7.31 (dd, J = 14.3, 7.6 
Hz, 2H), 7.12-7.20 (m, 4H), 6.13-6.17 (m, 1H), 6.09-6.12 (m, 1H), 5.91-5.97 (m, 1H), 5.46-
5.54 (m, 1H), 4.15-4.24 (m, 1H), 4.13 (t, J = 5.6 Hz 1H), 3.97-4.08 (m, 2H), 3.89 (td, J = 
15.8, 7.5 Hz, 1H), 3.12-3.23 (m, 1H), 2.91 (br, 1H), 2.73-2.84 (m, 1H), 1.63-1.76 (m, 1H), 
1.57 (p, J = 6.4 Hz, 2H), 1.20-1.36 (m, 28H), 0.89 (t, J = 6.9 Hz 3H), 0.83 (dd, J = 12.0, 
6.8 Hz, 2H), 0.56-0.63 (m, 2H). 13C NMR (125 MHz, CD3OD): δ 175.1, 161.7, 157.5, 
152.2, 152.1, 137.9, 137.1, 131.8, 130.7, 126.0, 121.4, 121.3, 114.8, 70.1, 70.0, 66.4, 
60.4, 51.5, 47.1, 35.5, 33.1, 30.8, 30.7, 30.6, 30.4, 30.3, 29.7, 26.9, 24.3, 23.7, 20.5, 
20.4, 14.4, 7.6; 31P NMR (CD3OD); 3.87, 3.56. MS-ES+ (m/z): calcd. for C37H56N7O5P, 
709.41 (100%), 710.41 (40.0%), 711.41 (7.8%); found, 710.4[M+H+]. 
AlaC18: 1H NMR (500 MHz, CD3OD): 7.64 (d, J = 6.0 Hz, 1H), 7.30 (dd, J = 14.2, 7.5 
Hz, 2H), 7.11-7.20 (m, 3H), 6.13-6.18 (m, 1H), 6.09-6.12 (m, 1H), 5.92-5.97 (m, 1H), 5.46-
5.55 (m, 1H), 4.14-4.24 (m, 1H), 4.13 (t, J = 5.6 Hz, 1H), 3.97-4.08 (m, 2H), 3.90 (td, J = 
15.6, 7.3 Hz, 1H), 3.12-3.23 (m, 1H), 2.91 (br, 1H), 2.72-2.83 (m, 1H), 1.63-1.75 (m, 1H), 
1.57 (p, J = 6.3 Hz, 2H), 1.20-1.35 (m, 33H), 0.89 (t, J = 6.9 Hz 3H), 0.83 (dd, J = 12.0, 
6.8 Hz, 2H), 0.56-0.62 (m, 2H). 13C NMR (125 MHz, CD3OD): δ 175.1, 161.9, 157.5, 
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152.3, 152.1, 138.6, 138.0, 137.9, 137.1, 136.9, 131.8, 130.7, 126.0, 121.4, 121.3, 70.1, 
70.0, 60.4, 60.3, 47.1, 37.0, 35.5, 33.1, 30.8, 30.7, 30.6, 30.5, 30.3, 29.7, 26.9, 24.3, 
23.7, 20.6, 20.4, 14.5, 7.6; 31P NMR (CD3OD); 3.86, 3.54. MS-ES+ (m/z): calcd. for 
C41H64N7O5P, 765.47 (100%), 766.47 (44.3%), 767.48 (9.6%); found, 766.4[M+H+]. 
AlaC22: 1H NMR (500 MHz, CD3OD): 7.64 (d, J = 5.7 Hz, 1H), 7.31 (dd, J = 13.9, 7.7 
Hz, 2H), 7.22-7.29 (m, 1H), 7.12-7.19 (m, 4H), 6.13-6.17 (m, 1H), 6.09-6.12 (m, 1H), 5.92-
5.97 (m, 1H), 4.15-4.24 (m, 1H), 4.14 (t, J = 5.6 Hz, 1H), 3.98-4.08 (m, 2H), 3.89 (td, J = 
15.5, 7.7 Hz, 1H), 3.12-3.24 (m, 1H), 2.91 (br, 1H), 2.72-2.84 (m, 1H), 1.61-1.76 (m, 1H), 
1.58 (p, J = 6.3 Hz, 2H), 1.17-1.38 (m, 42H), 0.89 (t, J = 6.9 Hz 3H), 0.84 (dd, J = 12.0, 
6.8 Hz, 2H), 0.56-0.62 (m, 2H). 13C NMR (125 MHz, CD3OD): δ 175.1, 161.9, 157.5, 
152.3, 152.2, 151.7, 137.9, 137.0, 131.8, 130.7, 126.0, 121.4, 121.3, 114.9, 70.1, 70.0, 
66.4, 60.5, 60.3, 51.7, 51.6, 47.1, 35.5, 33.1, 30.8, 30.7, 30.6, 30.5, 30.4, 29.7, 26.9, 
24.3, 23.7, 20.6, 20.4, 14.5, 7.6; 31P NMR (CD3OD); 3.86, 3.55. MS-ES+ (m/z): calcd. 
for C45H72N7O5P, 821.53 (100%), 822.54 (48.7%), 823.54 (11.6%); found, 822.5[M+H+]. 
PheC14: 1H NMR (500 MHz, CD3OD): 7.59 (s, 0.5H), 7.54 (s, 0.5H), 7.09-7.30 (m, 
8H), 7.02-7.07 (m, 2H), 6.01-6.05 (m, 1H), 5.86-5.94 (m, 1H), 5.42-5.49 (m, 1H), 4.09 (dd, 
J = 15.3, 8.9 Hz, 1H), 3.91-4.02 (m, 2H), 3.70-3.84 (m, 1H), 3.62-3.67 (m, 1H), 2.97-3.09 
(m, 1H), 2.78-2.95 (m, 3H), 2.68 (td, J = 14.7, 8.6 Hz 1H), 1.45-1.58 (m, 3H), 1.18-1.35 
(m, 23H), 0.89 (t, J = 6.8 Hz, 3H), 0.81-0.86 (m, 2H), 0.56-0.62 (m, 2H). 13C NMR (125 
MHz, CD3OD): δ 174.2, 161.9, 157.5, 152.2, 138.6, 138.4, 138.3, 138.0, 137.0, 131.7, 
131.6, 130.7, 130.6, 129.5, 127.9, 125.9, 121.4, 121.2, 114.9, 69.8, 66.4, 60.4, 58.1, 
57.9, 46.9, 41.0, 36.9, 35.5, 33.1, 30.8, 30.7, 30.6, 30.5, 30.3, 29.6, 26.9, 24.3, 23.7, 
14.5, 7.6; 31P NMR (CD3OD); 3.57, 3.24. MS-ES+ (m/z): calcd. for C43H60N7O5P, 785.44 
(100%), 786.44 (46.5%), 787.45 (10.6%); found, 786.4[M+H+]. 
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PheC18: 1H NMR (500 MHz, CD3OD): 7.59 (s, 0.5H), 7.54 (s, 0.5H), 7.08-7.32 (m, 
8H), 7.02-7.08 (m, 2H), 5.85-5.93 (m, 1H), 5.41-5.49 (m, 1H), 4.08 (dd, J = 17.9, 8.9 Hz, 
1H), 3.90-4.03 (m, 2H), 3.72-3.85 (m, 1H), 3.60-3.67 (m, 1H), 2.96-3.09 (m, 1H), 2.78-
2.95 (m, 3H), 2.68 (td, J = 15.4, 8.6 Hz 1H), 1.44-1.57 (m, 3H), 1.15-1.35 (m, 33H), 0.89 
(t, J = 6.8 Hz, 3H), 0.81-0.86 (m, 2H), 0.56-0.63 (m, 2H). 13C NMR (125 MHz, CD3OD): δ 
174.1, 161.7, 157.4, 152.2, 152.1, 151.6, 138.3, 138.2, 138.0, 137.9, 137.0, 131.6, 
130.7, 130.6, 130.5, 130.1, 130.0, 129.5, 127.9, 125.9, 121.3, 121.2, 114.8, 69.8, 69.7, 
66.4, 60.4, 58.0, 57.7, 46.9, 41.1, 41.0, 35.5, 33.1, 30.8, 30.6, 30.5, 30.4, 30.3, 29.6, 
24.4, 23.7, 14.5, 7.6; 31P NMR (CD3OD); 3.56, 3.24. MS-ES+ (m/z): calcd. for 
C47H68N7O5P, 841.50 (100%), 842.51 (50.8%), 843.51 (12.6%); found, 842.5[M+H+]. 
PheC22: 1H NMR (500 MHz, CD3OD): 7.59 (d, J = 28 Hz 1H), 6.95-7.44 (m, 11 H), 
6.04 (br, 1H), 5.88-5.95 (m, 1H), 5.48 (br, 1H), 4.13 (d, J = 15.2, 8.7 Hz 1H), 3.89-4.09 (m, 
3H), 3.47-3.59 (m, 2H), 2.64-3.15 (m, 5H), 1.45-1.64 (m, 3H), 1.07-1.39 (br, 42H), 0.91 (t, 
J = 6.6 Hz 3H), 0.84-0.87 (m, 2H), 0.61 (br, 2H). 13C NMR (125 MHz, CD3OD): δ 174.2, 
157.4, 154.3, 152.1, 144.9, 138.3, 138.2, 138.0, 137.9, 137.1, 131.5, 130.6, 130.5, 
130.3, 130.1, 129.6, 128.9, 127.9, 126.7, 125.9, 124.1, 121.9, 121.4, 121.3, 121.1, 
114.8, 69.9, 66.7, 66.4, 63.2, 60.4, 58.1, 57.8, 46.8, 41.1, 35.4, 33.1, 31.2, 30.7, 30.5, 
29.6, 29.5, 26.9, 23.8, 14.5, 7.6; 31P NMR (202 MHz, CD3OD); 3.25, 3.54. MS-ES+ (m/z): 
calcd. for C51H76N7O5P, 897.56 (100%), 898.57 (55.2%), 899.57 (14.9%); found, 898.56 
[M+H+]. 
4.5.3 Cell culture 
Human peripheral blood monocytes were obtained and cultured as previously 
described19,20. Briefly, monocytes were obtained by leukapheresis followed by purification 
via countercurrent centrifugal elutriation. Elutriated monocytes were cultured as adherent 
cells at 37 °C in a 5% CO2 incubator in DMEM supplemented with 10% heat-inactivated 
 101 
pooled human serum, 10 μg/mL ciprofloxacin, 50 μg/mL gentamicin, and 1000 U/mL 
recombinant macrophage colony stimulating factor. Seven days later, differentiated 
macrophages (MDM) were ready for study. Human T lymphoblastoid cell line CEM CD4+ 
and CEM-ss were obtained through NIH AIDS Reagent Program and maintained at 37°C 
in 5% CO2 in RPMI medium (Sigma) supplemented with 10% FBS and 1% Penicillin 
Streptomycin.  
4.5.4 EC50 and CC50 of ABC ProTides LA. 
The antiviral activities (EC50) of native ABC and ABC ProTides against HIV-1ADA were 
determined in MDM and CEM CD4+ T cells as previously described2. MDM or CEM CD4+ 
T cells were incubated with various concentrations of ABC or ABC ProTides for 60 min 
followed by infection with HIV-1ADA or HIV-1NLF-3 at a multiplicity of infection (MOI) of 0.01. 
The MDM or CEM CD4+ were washed extensively with phosphate buffered saline (PBS) 
to remove excess virus particles. The cells were incubated an additional 10 days in the 
presence of the same concentration of drug used before infection. Cell culture medium 
was changed every other day with replacement of equivalent drug containing media. At 
day 10 post infection, supernatants were collected for and analyzed by HIV reverse 
transcriptase assay. 
The cytotoxicity of ABC and its ProTides were measured by CellTiter-Blue® Cell 
Viability Assay. Briefly, MDM or CEM CD4+ T cells were plated in a 96-well plate and 
treated with 100 μl of 0 ~ 400 µM of ABC and its ProTides for 24 h. Then drug contained 
media were removed and replaced by fresh media, and 20 μl of CellTiter-Blue® reagent 
were added to each well followed by incubating the plate for 1-2 h in the incubator. The 
absorbance of each well was measured using a microplate reader with excitation 560 nm 
and emission 590 nm. The cell viability was calculated according to manufacturer’s 
instruction. 
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4.5.5 Metabolic stability of ABC ProTides  
The experiment was carried out by adding each ProTide into 300 μl human serum or 
rat serum to reach a final concentration of 15 ug/ml in glass vial, and duplicate samples 
were used for each ProTide. After incubating the samples at 37 °C with shaking for 6, 24 
h, 1.5 ml of MeOH was added to stop the reaction.  Samples were vortexed for 3 min, then 
centrifuged down at 17,000 g for 10 min. The supernatants were transfer to new 2 ml tubes 
and evaporated to dryness under vacuum. The samples were reconstituted using 50 μl of 
MeOH, vortexed for 3 min and centrifuged down at 17,000 g for 10 min. The supernatants 
were analyzed by HPLC for drug concentrations. For control sample (0 min), MeOH were 
added first to stop the enzyme before adding the ProTides.  
4.5.6 Measurements of Intracellular CBV-TP level 
Intracellular levels of CBV-TP were measured similar to previously described9. MDM 
or CEM CD4+ T cells were treated with 10 µM ABC and ABC ProTides. At 6, 24 and 48 h 
after treatment, MDM or CEM CD4+ T cells were collected in 70% MeOH. CBV-TP from 
MDM was extracted as previously described3, the samples were analyzed by LC-MS. 
4.5.7 Preparation and Characerization of ABC ProTides LA nanosuspensions. 
ABC ProTides LA nanosuspension were prepared by high-pressure homogenization 
(Avestin EmulsiFlex-C3; Avestin Inc., Ottawa, ON, Canada) as previously described. 
Briefly, ABC ProTides (1% w/v), DSPE-mPEG2k (0.2% w/v) and Tween 80 (0.2% w/v) were 
premixed in 10mM Phosphate buffer (pH 7.4) overnight at room temperature followed by 
homogenization at 20,000 psi until the desired particle size and polydispersity index (PDI) 
were achieved. Effective diameter (Deff), PdI, and ζ-potential were measured by dynamic 
light scattering (DLS) (Malvern Zetasizer Nano Series Nano-ZS, Malvern Instruments, 
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Westborough, MA, USA). Transmission Electron Microscope (TEM) was used to visualize 
the morphology of nanosuspensions.  
4.5.8 Cell uptake, retention and release of ABC ProTides LA nanosuspensions 
Uptake, retention and release of ABC ProTides nanosuspensions were determined 
with MDM as previously reported2,12,20-22. Briefly, MDM were treated with different 
nanosuspensions at a concentration of 50 µM for various time. At 1, 2, 4 and 8 h, adherent 
MDM were collected in 1 mL PBS after washing with 1 mL PBS twice. Then MDM were 
pelleted by centrifugation at 3000rpm for 8 min. The cell pellet was reconstituted in 200 µl 
methanol and probe sonication were briefly used to break the cells and help extract drugs. 
After probe sonication, centrifugation at 14,000 rpm for 10 min were used to pellet the cell 
debris. The supernatant was analyzed for prodrug content using HPLC. For retention and 
release, MDM were treated with 50 µM different nanosuspension for 8 h. Then 
nanosuspension contained media were replaced by fresh media after washing MDM with 
PBS twice. Half media change was conducted every other day with whole media change 
was conducted one day before collecting MDM. At day 1, 3, 7, 14, 21 and 28, MDM were 
collected in 1mL PBS after washing with 1 mL PBS twice. The media were also collected 
and stored in -20. The samples were processed as described above for analysis using 
HPLC.  
The intracellular levels of CBV-TP were also measured for cell uptake and retention 
study. Briefly, after MDM were pelleted by 3000 rpm for 8 min, 200 µl 70% MeOH was 
used for reconstitution. After the extraction of CBV-TP from MDM as previously reported3, 
the samples were analyzed by LC-MS. 
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4.5.9 In Vitro antiretroviral efficacy study with MDM. 
The study was conducted as previously described2,12,20-22. MDM were treated with 50 
µM different nanosuspension for 8 h. Then nanosuspension contained media were 
replaced by fresh media after washing MDM with PBS twice. Half media change was 
conducted every other day. At predetermined time point, days 1, 3 ,7, 14, 21 and 28, MDM 
were infected with HIV-1ADA and cultured with half media changed for an additional 10 
days. At days 10, supernatant was collected for RT assay and MDM were fixed and 
immunostained for expression of p24. Untreated, uninfected MDM served as negative 
controls (control), while MDM exposed to HIV-1ADA but not treated with nanosuspension, 
served as positive controls (HIV-1).  
4.5.10 In vivo pharmacokinetic study. 
Animal PK studies were conducted in accordance with the University of Nebraska 
Medical Center Institutional Animal Care and Use Committee. Male Sprague Dawley rat 
(250g; Jackson Labs, Bar Harbor, ME) were injected intramuscularly (i.m.) with ABC, 
NAlaC14, NAlaC18, NAlaC22 and NPheC18 (70 mg/kg ABC-eq.) intramuscularly (IM; 
caudal thigh muscle). Whole blood samples were collected at 1 h, 1, 7, 14, 21 and 28 days 
after injection. PBMC were separated from whole blood samples using HISTOPAQUE 




Figure 4.1 Design rationale and synthesis scheme of ABC ProTides LA.  
A. Design rationale of ABC ProTides LA. Monophosphate group protected by an 
aromatic group and an amino acid ester moiety, which can be enzymatically cleaved-off 
inside cells to release the free nucleoside monophosphate and monophosphonate species 
to increase the potency of drugs. Long-chain fatty alcohol of amino acid esters extend the 
release of drugs. B. Synthesis scheme of ABC ProTides LA. Reagent and conditions: 
a. long-chain fatty alcohol, HATU, imidazole, Et3N, DMF/CHCl3, 45 ℃, 48 h; b. Pd/C, 
Et3SiH, MeOH/CHCl3 (1:1 v/v), rt, 16 h; c. Phenyl dichlorophosphate, Et3N, CH2Cl2, -78 ℃-




Table 4.1 Antiretroviral activity and cytotoxicity of ABC and ABC ProTides LA in 
cell culturea 
Cpd Amino acid Esters 
EC50 (μM) for bCC50 (μM) for cSI 
MDM CEM CD4+ MDM CEM CD4+ MDM CEM CD4+ 
ABC - - 0.021 2.66 >400 >200 >19,000 >75 
AlaC14 L-Ala Myristyl 0.001 0.24 >100 >25 >100,000 >415 
AlaC18 L-Ala Stearyl 0.002 0.30 ~400 >100 ~200,000 ~1330 
AlaC22 L-Ala Docosyl 0.004 2.19 >200 >200 >50,000 >90 
PheC14 L-Phe Myristyl 0.0002 1.21 ~200 >12.5 >1,000,000 >10 
PheC18 L-Phe Stearyl 0.001 25.64 >400 >200 >400,000 >7.5 
PheC22 L-Phe Docosyl 0.003 43.03 ~200 >200 ~65,000 >4.5 
bCC50: 50% cytotoxic concentration. 







































Figure 4.6 Intracellular CBV-TP levels. 
Intracellular CBV-TP in MDM (A) and CEM CD4+ T cells. MDM or CEM CD4+ T cells 
were treated with 10 µM ABC and ABC ProTides. At 6, 24 and 48 h after treatment, MDM 
or CEM CD4+ T cells were collected in 70% MeOH. CBV-TP from MDM was extracted as 




Figure 4.7 Metabolic stability of ABC ProTides LA in sera. 
Metabolic stability of ABC ProTides LA in human serum (A) and rat serum (B).  
The experiment was carried out by adding each ProTide into 300 μl human serum or rat 
serum to reach a final concentration of 15 ug/ml in glass vial, and duplicate samples were 
used for each ProTide. After incubating the samples at 37 °C with shaking for 6, 24 h, 1.5 
ml of MeOH was added to stop the reaction.  Samples were vortexed for 3 min, then 
centrifuged down at 16,000 g for 10 min. The supernatants were transfer to new 2 ml tubes 
and evaporated to dryness under vacuum. The samples were reconstituted using 50 μl of 
MeOH, vortexed for 3 min and centrifuged down at 16,000 g for 10 min. The supernatants 
were analyzed by HPLC for drug concentrations.  For control sample (0 min), MeOH were 




Figure 4.8 Preparation and characterization of nanoformulated ABC ProTides 
LA. 
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(A) Preparation of nanoformulated ABC ProTides LA. ABC ProTides LA 
nanosuspension were prepared by high-pressure homogenization. ABC ProTides (1% 
w/v), DSPE-mPEG2k (0.2% w/v) and Tween 80 (0.2% w/v) were premixed in 10mM 
Phosphate buffer (pH 7.4) overnight at room temperature followed by homogenization at 
20,000 psi until the desired particle size and polydispersity index (PDI) were achieved. 
Effective diameter (Deff), PdI, and ζ-potential were measured by dynamic light 
scattering (DLS) (B) TEM images of the morphology of nanoformulated ABC 
ProTides LA.  
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Table 4.2 Characterization of nanoformulated ABC ProTides LA 





NAlaC14 231±3 0.20±0.03 -33.5±0.8 80% 
NAlaC18 242±2 0.28±0.04 --27.8±0.4 68% 
NAlaC22 286±23 0.34±0.01 -32.1±1.5 79% 
NPheC14 216±3 0.19±0.01 -37.5±1.2 74% 
NPheC18 247±7 0.32±0.04 -38.4±2.9 50% 
NPheC22 297±8 0.33±0.03 -39.0±3.0 53% 
Effective diameter (Deff), polydispersity index (PdI) and ζ- potential of nanoformulation 
samples diluted in water were determined by dynamic light scattering (DLS). Drug 
loadings of lyophilized nanoformulations were determined by HPLC. Drug loading (%) = 





Figure 4.9 Cell uptake, retention and release study in MDM. 
For uptake study, MDM were treated with different nanosuspensions at a 
concentration of 50 µM for various time. At 1, 2, 4 and 8 h, adherent MDM were collected 
in 1 mL, pelleted by centrifugation, then reconstituted in 200 µl methanol or 70% MeOH 
for prodrug (A) or CBV-TP (B) level measurements. For retention and release, MDM were 
treated with 50 µM different nanosuspension for 8 h. Then nanosuspension contained 
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media were replaced by fresh media after washing MDM with PBS twice. Half media 
change was conducted every other day with whole media change was conducted one day 
before collecting MDM. At day 1, 3, 7, 14, 21 and 28, MDM were collected in 1mL PBS, 
pelleted by centrifugation, then reconstituted in 200 µl methanol or 70% MeOH for prodrug 





Figure 4.10 p24 staining of MDM for antiretroviral efficacy study. 
MDM were treated with 50 µM different nanosuspension for 8 h. Then nanosuspension 
contained media were replaced by fresh media after washing MDM with PBS twice. Half 
media change was conducted every other day. At predetermined time point, days 1, 3 ,7, 
14, 21 and 28, MDM were infected with HIV-1ADA and cultured with half media changed for 
an additional 10 days. At days 10, supernatant was collected for RT assay and MDM were 
fixed and immunostained for expression of p24. Untreated, uninfected MDM served as 
negative controls (control), while MDM exposed to HIV-1ADA but not treated with 





Figure 4.11 Pharmacokinetic study of nanoformulated ABC ProTides LA. 
Male Sprague Dawley rat (250g; Jackson Labs, Bar Harbor, ME) were injected 
intramuscularly (i.m.) with ABC, NAlaC14, NAlaC18, NAlaC22 and NPheC18 (70 mg/kg 
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ABC-eq.) intramuscularly (IM; caudal thigh muscle). Whole blood samples were collected 
at 1 hr, 1, 7, 14, 21 and 28 days after injection. PBMC were separated from whole blood 
samples using HISTOPAQUE 1083 (Sigma# 1083-1) following manufacturer’s instruction. 
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Chapter 5  




In this project, we proved that ProTide technology can be useful for the development 
of ABC LA and be part of our LASER ART platform. ProTide technology was able to 
increase the antiretroviral potency of drugs as compared to ABC. In general, L-alanine 
based ProTides are more potent than L-phenylalnine based ProTides in CEM CD4+ T cells 
but not in MDM. In MDM, L-alanine based ProTides had higher Cmax of CBV-TP within the 
48 hr incubation, but L-Phenylalanine based ProTides had higher C48 of CBV-TP, which 
can explain the results of EC50 in MDM. But in CEM CD4+ T cells, L-alanine based 
ProTides had higher levels of CBV-TP for the whole 48 hr incubation. These results 
correlated with the EC50 results and it is possibly due to the lack of certain enzymes in 
CEM CD4+ T cells. 
The presence of long-chain fatty alcohol diminished the improvement of potency 
brought by ProTide technology, but some ABC ProTides stayed more potent as compared 
to ABC. In general, there were significantly negative correlation between chain length of 
fatty esters and drug potency against HIV-1. Besides that, ProTides with longer chain 
length of fatty esters appeared to be more stable in serum which is very important since 
presence of fatty acid esters improve membrane penetration of ProTides and will results 
in higher prodrug levels inside the cell.  
In summary, for the design of ABC LA with ProTides technology, there are at least two 
balances need to be considered. First is the balance between potency and extended 
release. Second is the balance between drug retained and released by MDM. At the end, 
these are all determined by the amino acid side chain and chain length of fatty esters.  
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5.2 Future directions 
First of all, our ABC ProTides nanosuspension can be prepared using either poloxamer, 
lipid derivatives, and tween as stabilizers. Different stabilizer might affect the 
pharmacokinetics of nanosuspensions in vivo. For example, the presence of multinucleate 
giant cells, prolonged macrophage infiltration of the formulation depot, and more persistent 
histiocytic infiltrate in the lymph nodes were observed in the tween 80-containing 
nanosuspension1, and these inflammation reactions not only can influence the overall 
tolerability of LA nanosuspensions but also affect the pharmacokinetics of LA 
nanosuspensions as macrophages served as secondary depots2. It is needed to optimize 
our formulations by exploring different stabilizers. 
Second, ProTides synthesized by general ProTides procedures yields a mixture of 
diastereoisomers. In some case, the two ProTides diastereoisomers had similar potency 
and can be pursued as mixtures. In other cases, one is more potent than the other 
because of different metabolism rates. For instance, the Sp diaestereoisomer of tenofovir 
alafenamide is 10-fold more potent against HIV than the Rp diastereoisomer3. Similar 
phenomenon was also reported for ABC ProTides4. In order to further improve the potency 
of ABC ProTides LA, it might be needed to separate diaestereoisomers or conduct 
asymmetric synthesis5. 
Third, species differences are well known and will affect the results of 
pharmacokinetics study for our LA formulations. First, the metabolic rates are different in 
different species. Faster clearance of RPV from muscles or skin in rats than dogs have 
been observed.  Second, muscle structures are different between species. Dogs have 
softer and more vascularized striated muscle, which results in great spreading and faster 
distribution of nanosuspension toward the blood circulation after IM administration. In rats, 
IM injections are often not truly IM due to their small muscles and therefore more 
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comparable with SC injections6, Third, the expression of enzyme is different among 
species. For example, Paraoxonase (PON) and butyrylcholinesterase (BChE) were 
ubiquitous in all species, but were highly expressed in primates and dogs, whereas 
carboxylesterases (CES) were only abundant in rabbits, mice and rats. And CES are very 
important for the degradation and activation of ABC ProTides and other prodrugs for LA 
formulation developments7.  
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